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Abstract 
Selenium (Se) is an essential trace mineral required in maintaining health in 
humans. Recent research has demonstrated that Se shows promise as an 
agent that can reduce the harmful side-effects of chemotherapy (CT) and 
radiotherapy (RT), while not compromising the effectiveness of treatment. 
Clinical evaluations using varying doses of Se have demonstrated a 
significant reduction in toxicity of CT and RT.  
Se supplementation appears to mediate its biological effects through four 
main mechanisms: Se treatment promotes the death of malignant cells, but 
not normal cells, through the differential effects on the endoplasmic 
reticulum stress response; it inhibits hypoxia-induced angiogenesis which is 
required by tumours for their blood supply; it enhances DNA repair in 
normal but not malignant cells; and it reverses cellular resistance to some 
cytotoxic drugs.  
The objectives of this thesis were to evaluate the biological characteristics 
of the differential impact of a Se compound, methylseleninic acid (MSA), 
on malignant and non-malignant human cells and how that modulates the 
effects of cisplatin chemotherapy and/or radiation. In parallel with this, 
similar evaluations were undertaken in patients receiving a Se compound or 
placebo in conjunction with cisplatin and radiation for head and neck 
squamous cell carcinoma (HNSCC). 
MSA induced differential effects in peripheral blood mononuclear cells 
(PBMC) obtained from healthy individuals compared to the monocytic 
leukaemia THP-1 cell-line. While MSA did not change PBMC viability, it 
reduced that of THP-1 cells in a concentration-dependent manner. 
Furthermore, MSA treatment enhanced the cytotoxicity of CT and RT 
toward THP-1 cells without compromising the survival of PBMC. This 
increased sensitivity in THP-1 cells is likely to be related to significantly 
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reduced levels of intracellular glutathione (GSH) in response to MSA. In 
contrast, GSH levels in PBMC rose substantially in response to MSA. 
Assessment of ER stress response proteins revealed that pro-survival 
proteins (GRP78, phospho-eIF2α, and spliced XBP-1) were upregulated in 
PBMC in response to MSA treatment. The malignant THP-1 cells had high 
levels of pro-survival proteins at baseline, which increased to a variable 
degree, especially caspase-8, in response to MSA. 
Putative pharmacodynamic markers of biological activity of Se were 
evaluated in plasma samples and PBMC from HNSCC patients in a 
randomised, placebo-controlled, double-blind phase II trial. Patients were 
treated with a 7-week radical course of concurrent cisplatin and RT (CRT) 
and were randomised to receive either selenomethionine (SLM) or matching 
placebo for 11 weeks, starting a week prior to CRT treatment. Because the 
trial is not yet complete, treatment allocation remains blinded and thus the 
pharmacodynamic results according to treatment with SLM or placebo 
cannot be made at the time of writing this thesis. However, markers of 
angiogenesis and the selenoprotein glutathione peroxidise 3 were measured 
and shown to significantly change during the course of treatment in a 
patient-specific manner. Lastly, ER stress markers were shown to be 
detected in PBMC obtained from patients during treatment.  
Se compounds differentially affect non-malignant and malignant cells. This 
results in increased therapeutic efficacy of cisplatin and RT targeting 
malignant cells. These effects appear to be mediated, at least in part, by 
modulation of intracellular GSH and ER stress response proteins. 
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Chapter 1  
Introduction and literature review 
1.1 Introduction 
Selenium (Se) is a remarkable element which has proven useful to humanity in a 
number of ways. Discovered in 1817 by the Swedish chemist Berzelius, Se was 
first considered to be solely toxic to humans, but this villainous view of Se has 
changed dramatically since it was recognized as an essential trace mineral 
required for maintaining health in humans and other species.  
1.2 Biogeography of Selenium 
Se is a ubiquitous element derived from the rocks and soils of our terrestrial 
environment. Most soils contain between 0.1 and 2.0 µg Se/kg (Swaine, 1955; 
Rosenfeld & Beath, 1964) however Se is unevenly distributed, which can result in 
Se-deficient areas or seleniferous (Se-rich) areas. Soils in some countries such as 
New Zealand, Denmark, Finland and in parts of China are known to be Se-
deficient. In contrast, other areas such as the great plains of the USA, Canada, 
Columbia, Venezuela, certain regions of China and Ireland have high levels of Se 
in soil and are therefore considered seleniferous. Biogeochemical mapping of top 
soils in New Zealand has shown that most soils are Se-deficient (Wells, 1967) due 
to either volcanic soil or excessive leaching which occur in the North and South 
Islands respectively. Most of the Se in food systems ultimately resides in the soil, 
entering the food system through plants. The biological availability of Se to plants 
depends on a number of factors including the species of Se, the pH of the soil, and 
the presence of other elements which can inhibit the uptake of Se. These factors 
ultimately influence the availability of Se to animals, including humans. 
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1.3 Human Intake 
The dietary intake of Se in human populations varies greatly throughout the world 
due to the uneven distribution of Se in soil and the varying nature of its 
bioavailability. Se was first recognized as an essential micronutrient when it was 
demonstrated Se could be used to replace vitamin E in rats and chicks to prevent 
vascular, muscular and hepatic lesions (Schwarz & Foltz, 1957; Schwarz et al. 
1957). Se deficiency-linked diseases in humans were subsequently identified in 
Se-deficient areas of China where dietary intake of Se was extremely low (≤10 
µg/day). Se deficiency has also been linked to the aetiology of Kashin-Beck 
disease, a deforming arthritis, and Keshan disease, an endemic cardiomyopathy 
prevalent in children (Zhou, et al., 2003). Keshan disease is believed to be 
triggered by coxsackie B viral infection, but Se supplementation remarkably 
prevents and reverses this disease. A number of other conditions have also been 
linked to Se deficiency, including male infertility, decreased immune and thyroid 
function, and increased cancer risk. 
1.4 Selenoproteins 
The beneficial impact of Se on human health has been attributed largely to the 
presence of Se in proteins termed selenoproteins. It is therefore crucial to 
understand the role and regulation of these proteins and their impact on human 
health. Selenium is unlike most other metals which interact with proteins as 
cofactors; instead Se is cotranslationally incorporated into a polypeptide chain in 
the form of selenocysteine (Sec). Sec is now well established as the 21
st
 
genetically encoded amino acid, incorporated at UGA codons, which are normally 
read as stop codons (Berry, et al., 1991; Kryukov, et al., 2003b). This unique 
situation of codon duality is controlled by the presence of evolutionary conserved 
cis- and trans-acting elements as well as a myriad of proteins  dedicated to 
decoding UGA into Sec. Proteins which contain Sec as part of their polypeptide 
chain are defined as selenoproteins. The human selenoproteome consists of 25 
identified selenoproteins, which are diversely expressed in tissues. These include 
glutathione peroxidases (5 genes), iodothyronine deiodinases (3 genes), 
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thioredoxin reductases (3 genes), selenophosphate synthetase 2, 15kDa-
selenoprotein as well as a host of other selenoproteins which have been annotated 
in alphabetical order (SelH, SelI, SelK, SelM, SelN, SelO, SelP/SepP, SelR, SelS, 
SelT, SelV, and SelW) (Kryukov, et al., 2003a). 
1.4.1 Selenocysteine biosynthesis 
Sec is unlike other amino acids being entirely synthesized on its own tRNA, 
designated tRNA 
[Ser]Sec
, using serine as an intermediate (B. J. Lee, Worland, 
Davis, Stadtman, & Hatfield, 1989). This unique tRNA has an anticodon that is 
complimentary to UGA, incorporating Sec in the presence of specialized 
secondary structures in the 3’ untranslated region (UTR) of selenoprotein 
mRNAs. One of the quirks in Sec biosynthesis is that it requires SPS2, which is 
itself a selenoprotein, suggesting that it is involved in the autoregulation of its 
own biosynthesis. SPS2 forms the active Se donor monoselenophosphate, which 
replaces the phosphate group of phosphoseryl-tRNA 
[Ser]Sec
 thereby forming 
selenocysteyl-tRNA 
[Ser]Sec
 which incorporates Sec into the polypeptide chain 
(Papp, et al., 2007). 
1.4.2 tRNA [Ser]Sec 
In humans, and all other mammals examined to date there is a single tRNA 
[Ser]Sec
 
gene (trsp) that encodes two isoforms differing by a single methyl group (D. L. 
Hatfield & Gladyshev, 2002), which changes the tertiary structure of the tRNA 
(D. Hatfield, Lee, Hampton, & Diamond, 1991). The relative distribution of the 
two isoforms is dependent on cell type, and can be altered in response to Se 
supplementation. Cell culture work has demonstrated that Se treatment induces 
the production of the methylated isoform (5-methylcarboxymethyluridine-2’-O-
methylribose) over the unmethylated isoform 5-methylcarboxymethyluridine 
(Chittum, et al., 1997; Diamond, et al., 1993; D. Hatfield, et al., 1991). 
1.4.3 Selenocysteine insertion sequence 
Though deletion studies have shown the requirement for tRNA 
[Ser]Sec
 in UGA 
recoding (Bosl, Takaku, Oshima, Nishimura, & Taketo, 1997), this unique tRNA 
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however, is not sufficient as the sole cause of UGA readthrough. The presence of 
specialized secondary structures in the 3’ UTR of selenoprotein mRNAs termed 
the selenocysteine insertion sequence (SECIS) element is the universal 
determinant of UGA recoding and can be located up to several kilobases away 
from the UGA codon (Berry, et al., 1991; Berry, Banu, Harney, & Larsen, 1993; 
Wilting, Schorling, Persson, & Bock, 1997). Studies have revealed that SECIS 
elements possess a conserved AAR motif with an apical loop which contains 
either two consecutive unpaired AA or CC (Korotkov, Novoselov, Hatfield, & 
Gladyshev, 2002; Kryukov, et al., 2003a) residues. Furthermore, SECIS elements 
contain what is termed the SECIS core, a stem structure containing non-Watson-
Crick G to A base pairing with either A or G residues preceding the core (Papp, et 
al., 2007). There are two SECIS elements depending on their structure shown in 
Figure 1. 
Figure 1: Two forms of eukaryotic SECIS elements (from Papp et al., 2007)  
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All selenoproteins depend on the presence of one SECIS element for Sec 
incorporation, except SelP, which requires two SECIS elements due to the 
presence of up to 18 UGA codons in its mRNA, and thus multiple sites for 
potential termination. In vitro mutational analysis of conserved SECIS sequence 
has shown that this element is absolutely essential for Sec incorporation, while 
mutations in non-conserved areas partially reduce recoding (Krol, 2002). This 
may mean that mutations in selenoprotein SECIS may contribute to the aetiology 
of disease in humans. In the 15 kDA selenoprotein the 1125G/A SNP (dbSNP 
refSNP: rs5859) in the SECIS of humans is distributed at a different frequency in 
individuals with cancer compared to apparently healthy individuals (Hu, et al., 
2001; Kumaraswamy, et al., 2000). Kumaraswamy and colleagues found that AA 
homozygotes were twice as frequent as GG homozygotes in cancer patients. 
Interestingly in vitro studies showed that the AA genotype was twice as efficient 
at promoting UGA recoding, but far less responsive to increased Se levels as well 
as the cells being more resistant to selenite-induced apoptosis (Apostolou, et al., 
2004; Kumaraswamy, et al., 2000). 
UGA readthrough additionally requires the cooperative action of several proteins. 
In mammals this process is rather complex involving SBP2 (Copeland & Driscoll, 
1999; Copeland, Fletcher, Carlson, Hatfield, & Driscoll, 2000), Sec-specific 
elongation factor (eEFSEC) (Fagegaltier, et al., 2000), ribosomal protein L30 
(Chavatte, Brown, & Driscoll, 2005), Secp43 (a 43 kDa RNA-binding protein), 
and soluble liver antigen (SLA) (Xu, et al., 2005). SBP2 is perhaps the most well-
characterized Sec incorporation factor. SBP2 was initially discovered to be 
involved in Sec incorporation in cell lysates. Cell lysates depleted of SBP2 lacked 
translational activity of selenoprotein synthesis, which was restored upon SBP2 
repletion (Copeland et al. 2000). Further studies reinforced the requirement of 
SBP2 for Sec incorporation by using siRNAs against SBP2 which caused global 
selenoprotein depletion (Papp, et al., 2007). In vitro studies with cell lysates have 
shown that SLA, Secp43 and tRNA 
[Ser]Sec
 form a complex and depletion of either 
protein factor decreases the binding of the other to tRNA 
[Ser]Sec
 and depletion of 
both causes depression of selenoprotein synthesis (Papp, et al., 2007). 
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1.4.4 Selenoprotein biology 
To date, most selenoproteins characterized have oxidoreductase activity with Sec 
found at the active site, where it is essential for efficient catalytic function. Sec 
differs from cysteine by a single atom (Se instead of S) which confers a lower pKa 
(5.2 v. 8.3), thus higher reactivity (Kim & Gladyshev, 2005). Selenoprotein 
homologues that have cysteine in place of Sec at their active site exhibit a 100-
fold decrease in their catalytic activity (Kim & Gladyshev, 2005). The 
bioavailability of Se affects both the expression and activity of many 
selenoproteins (Bermano, et al., 1995; Muller & Pallauf, 2003). Supplementation 
with Se results in increases in both selenoprotein expression, at mRNA and 
protein levels, and activity (Sunde, Raines, Barnes, & Evenson, 2009). Indeed, the 
current recommended daily allowance intakes of Se are based on the amount of 
dietary Se required to reach maximal activity of glutathione peroxidase (GPX). In 
human health, GPX 1 activity is lower in individuals with inadequate Se intake. 
Lei et al. (2007) showed that the activity of GPX is dependent on the Se 
concentration, with deficient intake reducing GPX 1 expression and activity. 
1.5 Selenium Chemoprevention 
Evidence for the anticancer properties of Se has come from a number of sources. 
Epidemiological studies have indicated inverse association of Se status and cancer 
risk; animal experiments have shown that supra-nutritional doses of Se reduce 
tumorigenesis; and clinical intervention trials have indicated Se supplementation 
may reduce cancer risk. 
1.5.1 Epidemiology 
Se deficiency was first proposed to be involved in the aetiology of cancer in the 
1960’s. Based on the observation that cancer mortality in the United States was 
inversely associated with Se content in forage crops (Kubota, Allaway, Carter, 
Gary, & Lazar, 1967), Shamberger and Frost (1969) postulated that Se had a role 
in the prevention of cancer. Other epidemiological studies have echoed these 
findings.  Shamberger and Willis (1971) found an increased risk of cancer 
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mortality from lymphomas and cancers of the gastrointestinal tract, peritoneum, 
lung, and breast in areas of the United States that have low Se content in forage 
crops. Using the same forage crop data, Clark et al. (1991) showed an increase 
risk of colorectal mortality in areas of low forage Se.  These findings are yet 
further supported by an analysis of apparent Se intake in 27 countries that 
indicated an inverse association of Se intake and total age-adjusted cancer 
mortality due to leukaemia and cancers of the colon, rectum, breast, ovary, and 
lung (Schrauzer, White, & Schneider, 1977). Moreover, a study conducted in 8 
provinces of China indicated a significant inverse association of blood Se levels 
and total cancer mortality rates (Yu, Li, Zhu, Yu, & Hou, 1989). These data 
generated a great deal on interest in Se as they indicated that this trace element 
could be a naturally-occurring anticarcinogen. 
1.5.2 Animal studies 
There have been numerous animal studies which have investigated the 
chemoprevention hypothesis of Se supplementation. Supranutritional doses of Se 
when supplemented in the diet, or drinking water, have been demonstrated by 
various researchers to protect laboratory animals from the development of 
mammary carcinomas (Ip, 1981; Ip & Ip, 1981; Ip & Sinha, 1981; Medina, Lane, 
& Shepherd, 1981; Medina & Shepherd, 1980; Schrauzer, White, & Schneider, 
1976; Tappel, 1965). Se supplementation has also been shown to prevent prostate 
cancer in rats (McCormick & Rao, 1999) as well as reduce the effect of DNA 
damage-inducing agents in canine prostate cells (Waters, et al., 2003). In a study 
involving male beagle dogs, which develop spontaneous prostate cancer, 
supplementation with SLM or selenized yeast for 7 months revealed up-regulated 
epithelial cell apoptosis in their prostates in Se supplemented dogs compared with 
controls (Waters, et al., 2003). Although several mechanisms for the 
chemopreventative effects of Se compounds have been proposed, Se-induced 
apoptosis is regarded as the most feasible mechanism (Rayman, 2005). 
1.5.3 In vitro studies 
Using cell culture systems, several research groups have demonstrated that Se 
treatment inhibits cellular growth and induces apoptosis in a dose-dependent 
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manner (Cho, Jung, & Chung, 1999; Jung, Zheng, Yoon, & Chung, 2001; Zeng, 
2002). Se compounds have been shown to be potent inducers of apoptosis in HL-
60 cells (Cho, et al., 1999; Jung, et al., 2001; Zeng, 2002), which was shown to be 
dependent on caspase activation. Furthermore, Se compound inhibition of cell 
growth and induction apoptosis appears to preferentially impact malignant cells 
over normal cells (Menter, Sabichi, & Lippman, 2000). Se compounds have also 
been shown to induce apoptosis in mammary cancer cell lines. Given these 
results, the manipulation of apoptosis can provide novel strategies in cancer 
chemoprevention, or possibly in cancer chemotherapeutics. 
1.5.4 Clinical prevention trials 
Intervention trials have been carried out in order to assess whether Se 
supplementation reduces the risk of particular cancers.  Some studies have 
investigated if hepatocellular carcinoma (HCC) incidence was reduced in response 
to Se supplementation.  One study in Qidong County in China involving 226 
hepatitis B antigen carriers - who are approximately 200 times more likely to 
develop HCC than non-carriers - showed no cases of HCC in individuals 
supplemented with 200 µg of selenized yeast, while 7 HCC cases developed in the 
placebo group over a four year period (Yu, Zhu, & Li, 1997).  In another study by 
the same group, HCC incidence fell by 35% in townships that had their salt 
fortified with sodium selenite (Na2SeO3) at 15 mg/kg while the incidence of HCC 
remained unchanged in control townships (Yu, et al., 1997). 
The Nutritional Prevention of Cancer (NPC) trial was the first double-blind 
placebo-controlled Se intervention trial carried out in a western (US) population.  
In this trial, 1312 individuals with a history of non-melanoma skin cancer were 
randomized to either placebo or 200 µg of Se per day as selenized yeast. There 
was no effect on the primary endpoint of non-melanoma skin cancer; however, 
secondary endpoints indicated fewer cancers of the prostate, colon and lung 
(Duffield-Lillico, Dalkin, et al., 2003; Duffield-Lillico, Slate, et al., 2003). 
Analysis of the NPC data showed that individuals in the lowest tertile of plasma 
Se (<106 ng/ml) at entry to the trial achieved the greatest effect with Se 
supplementation ((Duffield-Lillico, Dalkin, et al., 2003; Duffield-Lillico, Slate, et 
al., 2003). 
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The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was designed to 
specifically investigate the chemoprevention of prostate cancer. 35,533 healthy 
men, > 55 years old (> 50 years if African American), with normal rectal exams 
and prostate-specific antigen 4 ng/ml, were randomized to one of four arms: (i) 
200 µg/day l-selenomethionine, (ii) 400 IU/day all-rac-alpha-tocopheryl acetate 
(vitamin E), (iii) both supplements, or (iv) placebo for 7 to 12 years (Dunn, 
Richmond, Minasian, Ryan, & Ford, 2010). This study was however terminated 
prematurely due to concerns over safety and futility when interim analysis showed 
that neither supplement, alone or in combination, prevented prostate cancer in this 
population of men. These results provided a significant blow to the 
chemoprevention hypothesis regarding Se. It should be noted however, the NPC 
trial showed no benefit of Se supplementation in individuals with a baseline Se > 
123.2 ng/ml and prevention of prostate cancer was only evident after more than 5 
years (Duffield-Lillico, Dalkin, et al., 2003; Duffield-Lillico, Slate, et al., 2003). 
In the SELECT trial the upper 3 quartiles of both the placebo and treatment 
groups had a Se baseline > 123.2 ng/ml (Dunn, et al., 2010) and was terminated 
on an interim analysis conducted when median trial participation was less than 5 
years. These features indicate that this study, which was originally thought of as 
well-planned, had obvious faults. Furthermore, SELECT showed that one 
chemical form of Se was ineffective at protecting against prostate cancer. The 
chemical form used in this study was l-selenomethionine (SLM), which had 
already been shown in animal studies to be less effective in preventing prostate 
cancer in rats (McCormick & Rao, 1999) and DNA damage in canines (Waters, et 
al., 2003) compared with selenized yeast, which interestingly is the form used by 
the NPC trial (Duffield-Lillico, Dalkin, et al., 2003; Duffield-Lillico, Slate, et al., 
2003). 
1.6 Selenium and cancer treatment 
Although the vast majority of investigations involving Se have focused on 
chemoprevention, there are a number of studies which have illuminated the 
potential value of Se in conjunction with chemotherapeutic agents. The dose-
limiting toxicity of anticancer therapies is a major ongoing clinical issue.  
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Therefore establishing whether particular agents can usefully modulate the 
toxicity and efficacy of chemotherapy (CT) and radiotherapy (RT) is important. 
Preclinical work has demonstrated that Se compounds can reduce the toxicity of 
CT and RT while not compromising the efficacy of treatment. Se compounds have 
been shown to provide significant benefits in reducing the development of drug 
resistance (Caffrey & Frenkel, 2000a; Frenkel & Caffrey, 2001; Siddik, 2003), 
toxicity (S. S. Cao, A. Durrani, & Y. M. Rustum, 2004; Francescato, et al., 2001), 
and in improving antitumour efficacy (S. S. Cao, et al., 2004; M. G. Fakih, et al., 
2008; Fischer, Mihelc, Pollok, & Smith, 2007). The doses of Se which improve 
the narrow therapeutic index of anticancer treatments are far higher than those 
required to achieve homeostatic activity of selenoproteins, suggesting that 
different (non-selenoprotein-mediated) mechanisms come into play, such as 
disruption of protein folding. 
1.6.1 Animal studies 
In preclinical trials, supra-nutritional doses of Se compounds were found to both 
reduce irinotecan-induced toxicity and  increase irinotecan’s antitumour efficacy 
in nude mice bearing human tumour xenografts  (S. S. Cao, et al., 2004). This 
effect was not specific to a particular chemotherapeutic drug or tumour. Indeed, 
the effect of Se supplementation appears to be broad, enhancing the antitumour 
efficacy of cisplatin, carboplatin, oxaliplatin, irinotecan, docetaxel, fluorouracil 
and doxorubicin. Moreover, Se supplementation has been successfully used to 
treat a variety of human tumour xenografts, including small cell and non-small 
cell lung carcinoma, colorectal carcinoma and head and neck squamous cell 
carcinoma (HNSCC) (Caffrey & Frenkel, 2000a; S. S. Cao, et al., 2004; M. G. 
Fakih, et al., 2008; Fischer, et al., 2007; Frenkel & Caffrey, 2001). Pretreating 
tumour-bearing rats with methylselenocysteine (MSC) for 14 days before 
treatment with cisplatin 6mg/kg increased the tumour complete response (CR) rate 
from 25% to 75% while preventing stomatitis and diarrhoea. Furthermore, 9mg/kg 
of cisplatin was lethal in non-treated rats but tolerated in Se-treated rats, with a 
CR rate of 88% (S. S. Cao, et al., 2004). 
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1.6.2 Human studies 
Only a few small clinical trials have evaluated the effect of Se supplementation in 
combination with anticancer therapies. In one study, 62 women receiving 
chemotherapy for ovarian cancer (cisplatin 100 mg/m
2
 and cyclophosphamide 600 
mg/m
2
 every three weeks) were recruited into a double-blind trial. Patients were 
randomized to capsules with or without selenized yeast (200 µg per day) for three 
months, starting concurrently with chemotherapy. At three months patients 
supplemented with Se exhibited a significant reduction in toxicities compared to 
the control group (Sieja & Talerczyk, 2004). Furthermore, neutrophil counts at 
three months in the Se group were better maintained than in the untreated group 
(3.39 vs. 2.52 x 10
9
/l, p = 0.048) (Sieja & Talerczyk, 2004). In another 
randomized trial, women receiving adjuvant RT for gynaecological malignancies 
as well as oral selenite (500μg daily with RT and 300μg on non-RT days) were 
shown to have a significant increase in blood Se from 62.8 to 86.9 µg/l and 
reduced the incidence of > grade 2 diarrhoea from 46.6% to 21.0%. Other clinical 
randomized studies have reported similar findings regarding the reduction of 
measured toxicities in patients (Asfour, et al., 2009; Asfour, et al., 2006; Asfour, 
et al., 2007; Hu, et al., 1997).  
Fakih et al. (2008) conducted a phase I clinical trial to determine an appropriate 
oral dose of SLM required to achieve a plasma Se concentration of 15 µM or 
greater after one week. The authors demonstrated that doses of 4800 µg twice 
daily resulted in plasma Se greater than 15 µM at day eight, and that doses of up 
to 7200 µg twice daily for a week then once daily thereafter were generally well 
tolerated and resulted in even higher plasma Se concentrations. A plasma Se 
concentration of 15 µM or more is thought to provide therapeutic benefit, based 
on plasma Se concentrations in mice at which therapeutic effects were observed 
(S. S. Cao, et al., 2004). 
1.7 Mechanisms 
Se supplementation appears to mediate its biological effects through four main 
mechanisms. Se treatment: 1) enhances DNA repair in normal but not malignant 
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cells (Fischer, et al., 2007; Seo, Kelley, & Smith, 2002; Seo, Sweeney, & Smith, 
2002; Smith, Lancia, Mercer, & Ip, 2004); 2) promotes the death of malignant 
cells, but not normal cells, through the differential effects on the endoplasmic 
reticulum stress response (Wu, Zhang, Dong, Park, & Ip, 2005); 3) inhibits 
hypoxia-induced angiogenesis (C. Jiang, Ganther, & Lu, 2000; C. Jiang, Jiang, Ip, 
Ganther, & Lu, 1999); and 4) reverses cellular resistance to cytotoxic drugs 
(Caffrey & Frenkel, 1998, 2000a, 2000b; Frenkel & Caffrey, 2001). 
1.7.1 DNA repair 
The human body contains approximately 10
13
 cells that are exposed to an 
inordinate number of DNA lesions per day (Jackson & Bartek, 2009). This 
represents a dynamic equilibrium where cells have to maintain their nucleotide 
sequence in the face of processes which generate such lesions. There are three 
main influences on the magnitude and diversity of lesions. First, the 
physicochemical properties of DNA do not guarantee permanent stability, as some 
bonds can spontaneously break under physiological conditions. Spontaneous 
hydrolytic or deamination reactions can occur leaving non-instructive abasic sites 
or miscoding bases respectively (Hoeijmakers, 2001). Second, the genesis of 
lesions can be due to normal physiological processes such as DNA mismatches 
introduced through DNA replication, or via the action of reactive oxygen species 
(ROS) generated through aerobic metabolism. Finally, DNA lesions can also be 
introduced through external environmental factors. The most pervasive external 
source of DNA damage is ultraviolet light, in which residual rays of ultraviolet A 
and B can induce 100,000 lesions per cell per hour (Jackson & Bartek, 2009). 
Other prevalent environmental DNA damaging agents are ionizing radiation and 
environmental genotoxins. The most prevalent environmental cancer-causing 
agent is, of course, tobacco smoke, which is known to cause various cancers, in 
particular those of the lung, oral cavity and adjacent tissues. 
Many DNA lesions can block genome replication and transcription that in turn 
can lead to mutations or genome-wide DNA aberrations if they are not repaired 
correctly. Due to there being a multitude of different DNA lesions induced by 
various factors, cells have evolved multiple DNA-repair mechanisms – known 
collectively as the DNA-damage response (DDR) – in order to detect and repair 
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DNA lesions. Deficiency in the DDR pathway is a known causative factor in a 
number of human diseases, including some cancers.  
There are a number of DDR pathways operating in mammals that respond to 
different lesions but generally follow a common program of response as illustrated 
in Figure 2. While there are some lesions that can corrected through direct 
protein-mediated reversal, most DNA lesions require the synchrony of multiple 
and sophisticated protein interactions and catalytic events. 
It is evident that the wide diversity of DNA lesions had lead to the evolution of a 
diverse repertoire of DDR pathways (Table 1), however only the nucleotide 
excision repair (NER) pathway will be discussed in further detail.  
Figure 2: Model for the DNA-damage response. The presence of DNA lesions 
are recognised by various sensors that initiate signalling pathways (adapted 
from Jackson & Bartek 2009)  
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Table 1: DNA-damage response pathways (adapted from Jackson & Bartek 
2009) 
NER is perhaps the most versatile pathway of the DDR, recognizing a wide class 
of helix-distorting lesions that interfere with DNA replication and transcription. 
There are three main syndromes that are known to be caused by inborn mutations 
of NER factors: xeroderma pigmentosum, Cockayne syndrome, and 
trichothriodystrophy which are all characterized by sun sensitivity. NER is 
responsible for removing bulky lesions such as the 6-4 photoproducts caused by 
UV radiation which results in NER-defective xeroderma pigmentosum individuals 
exhibiting greater than 1000-fold increase in sun-induced cancers (Jackson & 
Bartek, 2009) 
 NER consists of two sub-pathways which differ only in their mechanism of 
lesion recognition: global genomic repair (GGR) which surveys the entire 
genome, and transcription-coupled repair (TCR) which targets transcription-
blocking DNA lesions. The initial recognition step of damaged DNA in these 
pathways is different, but subsequent steps involve the same proteins. The tumour 
suppressor p53 is a tetrameric transcription factor which mediates the induction of 
numerous genes involved in DDR pathways. In particular p53 directly modulates 
Pathway Type of damage Damaging agents/causes 
Nucleotide-excision repair 
(NER) 
CPD; (6-4) photoproducts UV; cisplatin; 4-
nitroquinoline oxide; and 
other oxidative damages 
Base-excision repair (BER) Single-base DNA damage 
(short-patch BER); single-strand 
break (long-patch BER) 
Oxidizing, methylating, 
alkylating agents; ionizing 
radiation 
Mismatch repair (MMR) Mispaired nucleotides; 
insertion/deletion loops 
Slippage of polymerase during 
replication 
Non-homologous end-
joining (NHEJ) 
Double-strand break Ionizing radiation; chemical 
agents such as 
neocarsinostatin 
Homologous recombination 
(HR) 
Double-strand break Ionizing radiation; chemical 
agents such as 
neocarsinostatin 
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GGR by recognizing NER-type DNA lesions thereby initiating their repair. p53 
modulates GGR through the expression of p48 and GADD45 which have roles in 
DNA lesion recognition, and chromatin assembly and repair respectively. Defects 
or overexpression of these factors can contribute to the sensitivity of normal and 
malignant cells to current therapies. 
1.7.2 Cancer and DNA repair 
The most prevalent non-surgical interventions for cancer are radiotherapy and 
chemotherapy. Both of these therapies function by generating DNA damage, thus 
it is essential to understand DDR pathways in order to increase efficacy of 
anticancer treatment. 
1.7.3 Cisplatin and DNA repair 
Presently, cisplatin (cis-diamminedichloroplatinum(II)) is one of the most widely 
used anticancer drugs, and displays clinical activity towards a number of tumours, 
including head and neck, testicular, small cell lung, and a number of other solid 
tumours (Jamieson & Lippard, 1999). The use of cisplatin as an anticancer drug 
has its origins in a serendipitous discovery by Rosenberg and colleagues in 1965 
studying Escherichia coli cell division in response to an electrical current applied 
to the growth medium. It was quickly realized that the inhibition of cell division 
was not due to the electrical current, but rather due to the formation of tetravalent 
complexes from the reaction of platinum derived from the electrodes with 
ammonium chloride from the growth medium (Rosenberg, Vancamp, & Krigas, 
1965). The cytotoxicity of cisplatin is ascribed to its interaction with nucleophilic 
N7 sites of purine bases in DNA. Cisplatin has the potential to form DNA-protein 
and DNA-DNA intrastrand and interstrand crosslinks. The current consensus view 
is that the cytotoxic effect of cisplatin can be largely attributed to DNA-DNA 
intrastrand crosslinks. This is consistent with the observation of Kelland (1993) 
that 1,2-intrastrand ApG and CpG crosslinks account for approximately 90% of 
total lesions.  
Platinum-DNA adducts formed in response to platinum-containing 
chemotherapeutics are repaired by the NER pathway. However, this repair is very 
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inefficient in vivo and can be attributed to the binding of high-mobility-group 
(HMG) proteins to cisplatin adducts, which inhibits their repair (Moggs, 
Szymkowski, Yamada, Karran, & Wood, 1997; Zamble, Mu, Reardon, Sancar, & 
Lippard, 1996) and the low level of DNA-repair proteins XPA and ERCC1-XPF 
in particular tissues (D. Wang & Lippard, 2005). Inhibition of repair by HMG 
proteins is probably due to shielding of adducts from NER damage-recognition 
factors. However, this shielding is incomplete, as cells with endogenous levels of 
HMG1 can repair G^G adducts, whereas addition of excess HMG1 completely 
abrogates repair (Evans, Moggs, Hwang, Egly, & Wood, 1997; Huang, Zamble, 
Reardon, Lippard, & Sancar, 1994). The DNA lesion recognition protein p48 is 
upregulated by BRAC1 in a p53-dependent manner following cisplatin treatment 
(D. Wang & Lippard, 2005) which may in part serve to explain why cells 
deficient in GGR display heightened sensitivity towards cisplatin treatment. 
Conversely, cells which express enhanced levels of NER factors have been shown 
to be resistant to cisplatin treatment (Dabholkar, Vionnet, Bostickbruton, Yu, & 
Reed, 1994; Q. D. Li, et al., 1998; States & Reed, 1996) 
1.7.4 Se and DNA repair 
The initial recognition step for GGR is controlled by p53 through its 
transcriptional control of the DNA damage-recognition proteins xeroderma 
pigmentosum complement groups C (XPC) and E (XPE). Interestingly, Se 
administration induces the expression of NER damage-recognition factors in a 
p53-dependent manner (Fischer, et al., 2007). Using two cell lines, one which 
contained active p53, the other containing an inactive mutant, Fischer and 
colleagues showed that treating cells with Se induced the expression of repair 
factors XPC and p48XPE only in p53
+/+
 cells. Furthermore, this selective 
induction of NER repair factors in p53 cells provided enhanced repair rates and 
protection against UV radiation and cisplatin. 
Redox regulation is critical for numerous proteins, including the activity of p53. 
SLM has been shown to modulate p53 activity independent of DNA damage 
through redox mechanisms (Seo, Kelley, et al., 2002). By using an assay based on 
reacting free sulfhydryl groups with N-ethylmaleimide, SLM was shown to 
promote the reduction of p53 cysteine residues. The authors then demonstrated 
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that this redox mechanism requires Ref1. Cells depleted of Ref1 with either RNAi 
or a dominant-negative Ref1 abrogated p53 reduction. p53 activity can be 
modulated by an antioxidant mechanism involving Se compounds, thereby 
protecting cells from DNA damage. Indeed, Seo and colleagues showed using UV 
radiation that SLM treatment protects from DNA damage only in cells which 
contain a functional copy of p53.  
Smith and colleagues (2004) using a p53 reporter gene showed that SLM, 
methylseleninic acid (MSA), and sodium selenite all affected p53 activity through 
transactivation of a reporter construct. However, it would appear that different 
chemical forms of Se appear to have differential impacts on p53 post-translational 
modification. As shown previously (Seo, Kelley, et al., 2002), SLM modifies key 
p53 cysteine residues. MSA was shown to induce phosphorylation of one or more 
p53 threonine residues while having no impact on p53 serine phosphorylation. 
Selenite however, induced phosphorylation of serine 20, 37, and 46, residues 
known to modulate apoptosis (Smith, et al., 2004). These results illustrate that 
protection from DNA damage provided by Se treatment is dependent on the 
species of Se used and the p53 status of the cell. Since by definition cells without 
functional p53 are malignant, Se treatment may provide a unique way of 
differentiating normal from malignant cells, through promoting the death of 
malignant cells while enhancing the DNA repair capacity of non-malignant cells. 
1.8 Apoptosis 
Multicellular organisms require a dedicated program that removes excess or 
potentially dangerous cells. Programmed cell death, or apoptosis, is an essential 
cellular process required to maintain homeostasis. Apoptosis is characterized by 
many distinct morphological changes that distinguish this process from necrosis. 
Given that induction of apoptosis is considered an essential process in the 
therapeutic efficacy of anticancer therapies, it is essential to understand the 
molecular mechanisms that govern this pathway. A family of cysteine proteases 
are responsible for most of the morphological changes observed in cells 
undergoing apoptosis (Hengartner, 2000). These death proteases are part of a large 
protein family know as caspases(Hengartner, 2000). Caspases are the central 
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executioners of apoptosis and inhibition of effecter caspase using small 
pharmacological agents has been shown to inhibit apoptotic cell death (Chau, 
Cheng, Kerr, & Hardwick, 2000). There are two main apoptotic pathways; the 
extrinsic death-receptor pathway, and the intrinsic mitochondrial pathway. There 
is however, a third pathway, involving the endoplasmic reticulum (ER) that will 
be discussed later. Caspase-8 is the key initiator of the extrinsic death-receptor 
pathway, and caspase-9 initiates the intrinsic mitochondrial pathway. 
Interestingly, Se treatment has been shown to activate apoptosis through caspase-8 
activation. 
1.8.1 Se and caspase-8 
Previous studies have shown Se treatment induces apoptosis in prostate cancer 
cells through capase-8 activation (Jiang et al. 2001). Li et al. (2007) showed 
enhanced apoptosis in MCF-7 breast cancer cells in response to Se and 
doxorubicin treatment. The authors were able to show that this synergistic effect 
was caused by indirect activation of both intrinsic and extrinsic pathways. In 
another study Maiko et al. (2010), using four cell lines and various Se compounds, 
demonstrated the presence of high levels of caspase-8 during apoptosis. Finally, 
Li et al. (2008) showed that Se-enhanced apoptosis of breast cancer cells involved 
caspase-8 activation. It should be noted however, that the authors demonstrated 
that capsase-8 activation followed caspase-9 activation, indicating Se-induced 
activation of caspase-8 may require cross-talk between intrinsic and extrinsic 
apoptotic pathways. These results indicate that the Se-induced apoptosis is, in 
part, reliant on the activation of caspase-8. 
1.8.2 Cell cycle and apoptosis 
Advancements in our basic understanding of cell cycle physiology and apoptosis 
have lead to an increased understanding of the effects of chemotherapy and 
radiation on normal and malignant cells. The mechanism by which cells divide is 
known as the cell cycle and is characterized by four distinct phases (G1, S, G2, M). 
It is apparent that sensitivity towards various chemotherapy drugs depends on the 
cell cycle. Apoptosis (discussed in section  1.8) and the cell cycle are intimately 
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related as cells that undergo growth arrest may be resistant to cytotoxic agents 
(Shah & Schwartz, 2001).  
Se compounds are well known to inhibit cell cycle progression, and induce 
apoptosis in malignant cell lines (Jung, et al., 2001; Z. S. Wang, Jiang, & Lu, 
2002; Zeng, 2002). The active moiety of the observed effects of Se compounds is 
considered to be methylselenol (Evans, et al., 1997; Ip, Dong, & Ganther, 2002), 
and precursors that directly generate methylselenol have been shown to be very 
effective in tumour inhibition (Ip, Thompson, Zhu, & Ganther, 2000). MSA is 
useful in cell culture studies since it does not require a beta-lyase reaction to 
release the active methylselenol moiety, instead, MSA directly provides 
methylselenol through non-enzymatic reduction (Ip, et al., 2000). 
1.9 ER stress 
Among the myriad of cellular processes required to maintain cellular homeostasis 
it is essential that all newly-synthesized proteins fold correctly and localize to the 
correct cellular compartments. In eukaryotic cells the ER is the organelle 
responsible for folding, export, secretion, and initial post-translational 
modifications of newly-synthesized proteins. Nascent proteins enter into the ER 
lumen through the translocon as unfolded polypeptide chains where they are 
directed down productive folding pathways by ER-resident chaperones. There are 
several factors involved in the efficient folding of proteins in the ER, and the ER 
is very sensitive to any factors which perturb normal protein folding, which may 
result in the accumulation of naive or aberrantly-folded proteins.  
The demand on the folding capacity of the ER will vary amongst different cell 
types and through the cellular life cycle in response to extracellular stimuli or cell 
cycle progression. The folding capacity of the ER can be overwhelmed transiently 
as extracellular stimuli alter a cell’s expression patterns, or more permanently due 
to genetic mutations preventing the correct folding of their respective proteins 
(Bernales, Papa, & Walter, 2006). Perturbations in protein folding can also result 
from alterations in ER homeostasis in response to redox reactions, nutrient 
deprivation, hypoxia, alterations in calcium balance, viral infection, and heat-
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induced protein denaturation. This is known as ER stress, a state which is toxic to 
cells, thus cells have evolved various protective strategies in order to cope with 
and counteract the deleterious effects of ER stress. These various protective 
strategies are collectively amalgamated as an intracellular ER-to-nucleus signal 
transduction pathway termed the unfolded protein response (UPR).  
This complex signalling pathway is induced in order to help cells cope with ER 
stress, though if large accumulations of aberrantly-folded proteins persist 
degradative pathways will be induced, causing cells to undergo apoptosis. The 
pro-survival effects of the UPR are mediated through three main mechanisms (i) 
inhibition of eukaryotic initiation factor 2α (eIF2α) or cap-dependent protein 
translation, (ii) enhanced translation of ER chaperones to enhance ER folding 
capacity, and (iii) ER-associated degradation which degrades misfolded proteins 
within the ER.  
The UPR is governed through three transmembrane receptors: pancreatic ER 
kinase (PKR)-like ER kinase (PERK), activating transcription factor 6 (ATF6), 
and inositol-requiring enzyme 1 (IRE1).  All three transmembrane receptors are 
maintained in an inactivated state through the association of their N-terminal 
domains with the ER chaperone GRP78, which is considered the gatekeeper to 
activation of all three branches of the UPR. Free GRP78 is present at low levels 
however, upon accumulation of unfolded proteins in the ER, GRP78 dissociates 
from the three receptors in order to bind aberrantly-folded proteins, thus leading to 
their activation (Bertolotti, Zhang, Hendershot, Harding, & Ron, 2000). The UPR 
pathway is illustrated in Figure 3. 
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Figure 3: Unfolded protein response. On aggregation of unfolded proteins in 
the ER lumen GRP78 dissociates from the three transmembrane receptors 
(IRE1, ATF6 and PERK), resulting in their activation (from Szegezdi et al., 
2006). 
1.9.1 Survival signalling pathways 
1.9.1.1 PERK 
Dissociation of GRP78 allows the ER-localized type 1 membrane protein PERK 
to oligomerize, resulting in its activation through autophosphorylation of the 
serine/threonine kinase domains (Bernales, et al., 2006). Active PERK 
phosphorylates Ser 51 of eIF2α causing global inhibition of eIF2α and cap-
dependent translation by inhibiting the guanine nucleotide exchange factor eIF2 
which recycles eIF2 to its active GTP-bound form (Krishnamoorthy, Pavitt, 
Zhang, Dever, & Hinnebusch, 2001). Inactivation of elF2α lessens the burden of 
naïve and aberrantly-folded proteins in the ER and causes a rapid decrease in the 
concentration of cyclin D1 resulting in G1 cell cycle arrest (Brewer & Diehl, 
2000; Brewer, Hendershot, Sherr, & Diehl, 1999; Niwa & Walter, 2000). The 
importance of temporal translation inhibition for cell survival has been 
demonstrated in PERK 
-/- cells. Phosphorylation of elF2α and reduced protein 
synthesis in response to ER stress is lost in Perk 
-/-
 cells (Harding, Zhang, 
Bertolotti, Zeng, & Ron, 2000; Koumenis, et al., 2002) and mutant cells are more 
susceptible to cell death in response to ER stress-inducing agents. Furthermore, 
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cell death due to ER stress in PERK-deficient cells was reduced when protein 
synthesis was inhibited by cyclohexamide (Harding, et al., 2000). 
Transcription of UPR target genes is also activated in response to the PERK-
mediated survival pathway. Translational inhibition induced by phosphorylation 
of eIF2α is not universal to all transcripts, and can be bypassed if mRNA 
transcripts contain certain regulatory sequences in their 5’ untranslated region 
(UTR), such as an internal ribosomal entry site (IRES). In this way expression of 
the UPR transcription factor ATF4 is induced by PERK activation (Harding, et 
al., 2000; Scheuner, et al., 2001). ATF4 is a cAMP response element-binding 
transcription factor (C/EBP) that promotes cell survival by inducing genes 
involved in redox reactions, amino-acid metabolism, stress response, and protein 
secretion (Harding, et al., 2003). However not all proteins induced by ATF4 are 
pro-survival; the expression of the transcription factor C/EBP induces 
homologous protein/growth arrest DNA damage (CHOP/GADD153), which 
promotes apoptosis, is highly dependent on ATF4 and will be detailed later. 
1.9.1.2 ATF6 
Transcriptional induction of pro-survival genes is mediated by the cis-acting ER 
stress response element (ERSE) in their promoter, with the consensus sequence 
CCAAT-N9-CCACG9 (Yoshida, Haze, Yanagi, Yura, & Mori, 1998). Two 
mammalian proteins, XBP1 and ATF6, have been identified as ERSE-binding 
proteins. ATF6 is a basic leucine zipper protein constitutively expressed as a type 
II transmembrane protein in the ER. In response to ER stress, ATF6 translocates 
from the ER membrane to the Golgi apparatus upon GRP78 dissociation. Upon 
arrival in the Golgi apparatus ATF6 is processed into its active form by site 1 
(S1P) and site 2 (S2P) proteases. S1P and S2P cleavage of ATF6 liberates the N-
terminal cytoplasmic domain - which contains a bZIP domain - after which the 
activated transcription factor translocates to the nucleus and, in conjunction with 
the nuclear factor Y transcription factors, induces genes with ERSE containing 
promoters. ATF6 has been shown to induce ER-resident chaperones such as 
GRP78 (Hong, Li, Mao, & Lee, 2004), GRP94 (Yoshida, et al., 1998), and protein 
disulfide isomerases (Szegezdi, Logue, Gorman, & Samali, 2006) thereby 
preventing the aggregation of aberrantly-folded proteins and enhancing the 
folding capacity of the ER. Other identified targets to date include the 
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transcription factors CHOP and X box-binding protein 1 (XBP1). Although 
CHOP expression is induced there are no reports of ATF6-induced apoptosis 
(Szegezdi, et al., 2006) 
1.9.1.3 IRE1 
IRE1 is a type 1 transmembrane protein which possesses a serine–threonine 
kinase domain and an endoribonuclease domain (Sidrauski & Walter, 1997). On 
activation, IRE1 oligomerizes in the ER membrane allowing the juxtaposed kinase 
domains to autophosphorylate. Activation of IRE1 may be caused by either 
binding of naïve or aberrantly-folded proteins to the IRE1 lumenal domain, or the 
release of repressing chaperones, or both (Ron & Hubbard, 2008). Subsequently, 
the trans-autophosphorylation of the IRE1 kinase domain activates the 
endonuclease activity of IRE1. IRE1 is then free to participate in an 
unconventional cytosolic mRNA-splicing reaction, removing a 26-nucleotide 
intron from the XBP1 mRNA induced previously by ATF6. The XBP1 mRNA 
encodes a nonfunctional protein which is activated by this unconventional splicing 
event, resulting in a frameshift, thus generating a mature XBP1 protein with a 
potent transactivation domain (Yoshida, Matsui, Yamamoto, Okada, & Mori, 
2001). This spliced variant is a potent activator of ER chaperones and HSP40 
family member P58
IPK 
(A. H. Lee, Iwakoshi, & Glimcher, 2003), which also has 
the ERSE. 
The activation of P58
IPK 
is not an immediate event but occurs somewhat after
 
the 
initial ER stress. P58
IPK 
expression represents a negative feedback loop in the 
UPR as P58
IPK 
binds and inhibits PERK, thus relieving the translational block. 
P58
IPK 
induction therefore represents the end of the UPR where, if the UPR has 
been successful, cells will return to normal function or, if unsuccessful, allow the 
synthesis of proteins involved in apoptotic pathways. However, the pro-apoptotic 
nature of P58
IPK 
has not been confirmed as P58
IPK -/- 
mice exhibited increased 
pancreatic apoptosis leading to diabetes (Ladiges, et al., 2005). This is most likely 
due to prolonged PERK inactivation leading to the depletion of essential proteins 
that are eIF2α- and cap-dependent. 
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1.9.2 Apoptosis Signalling Pathways 
Prolonged ER stress can trigger pro-apoptotic signalling pathways mediated by all 
three UPR transmembrane receptors. Cell death is not initiated directly by these 
receptors, but rather executed by downstream effectors induced by the UPR 
signalling cascades. Induction of CHOP was initially identified in response to 
DNA damage, but subsequently shown to also mediate ER stress-induced 
apoptosis, the latter probably being a more potent activator of CHOP induction 
(Oyadomari & Mori, 2004; Zinszner, et al., 1998). The role of CHOP in ER 
stress-induced apoptosis has been demonstrated in CHOP 
-/-
 mouse embryonic 
fibroblasts which show an increased resistance to ER stress-induced apoptosis 
(Zinszner, et al., 1998). CHOP expression may be induced by all three branches of 
the UPR, but PERK mediated induction of ATF4 is essential. Heterodimerization 
of ATF4 and CCAAT/enhancer binding protein β (C/EBP-β) activates the 
expression of CHOP (Fawcett, Martindale, Guyton, Hai, & Holbrook, 1999) 
resulting in the regulation of various genes involved in cell death. 
Activated IRE1 is also involved in ER stress-induced apoptosis. Overexpression 
of IRE1 in HEK293T cells was demonstrated to induce apoptosis (X. Z. Wang, et 
al., 1998). IRE1 is thought to promote apoptosis through the activation of the c-
Jun N-terminal kinase (JNK) pathway (Szegezdi, et al., 2006). ER stress-induced 
JNK activation, which regulates apoptotic machinery through BCL2 proteins 
(Davis, 2000), has been shown to be IRE1- and TNF-receptor-associated factor 2 
(TRAF2)-dependent. IRE1 further potentiates apoptosis through association with 
the adaptor TRAF2. This complex recruits apoptosis signal-regulating kinase 
(ASK1). Neurons from Ask1
-/-
 mice have been shown to be resistant to ER stress-
induced apoptosis, while overexpression of ASK1 was shown to enhance 
apoptosis in various cell culture models (Hatai, et al., 2000; Nishitoh, et al., 2002). 
1.9.3 Selenium and ER stress 
Se compounds have been shown to induce ER stress through the induction of 
UPR proteins. In vitro investigations in PC-3 human prostate cancer showed that 
low doses of MSA preferentially activated the pro-survival branch of the UPR 
(Wu, et al., 2005). Using three signature ER stress markers (phospho-PERK, 
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phospho-eIF2α, and GRP78) Wu and colleagues showed that MSA induced these 
targets in a time- and dose-dependent manner. Prolonged exposure, as well as 
high concentrations of MSA induced an apoptotic response through the induction 
of CHOP and cleaved caspase 12 (Wu, et al., 2005). 
1.10  Angiogenesis 
Angiogenesis is defined as the formation of new blood vessels from existing 
vasculature. Although angiogenesis is fundamental in homeostasis through tissue 
repair, embryonic development and fertility (Carmeliet, 2005), it is also well 
known to be involved in promoting tumour growth and metastasis (Avraamides, 
Garmy-Susini, & Varner, 2008; Carmeliet, 2005). The family of transcription 
factors known as hypoxia-inducible factors (HIF) are essential for regulating 
cellular pathways involved in angiogenesis (Giaccia, Siim, & Johnson, 2003), 
promoting the transcription of genes such as vascular endothelial growth factor 
(VEGF) under low oxygen conditions.  
At the onset of tumour growth expanding lesions are able to uptake nutrients and 
expel waste through diffusion. However, if these micro-tumours are to grow 
beyond approximately 3mm
3
, diffusion alone is not sufficient to support growth. 
For lesions to grow beyond the size limit imposed by diffusion, tumour growth is 
fully reliant on the ability to promote new blood vessel formation. Therefore, 
there have been intensive efforts to develop strategies to inhibit angiogenesis in 
cancer. Agents which inhibit angiogenesis are of clinical importance and interest 
and have been used successfully against particular types of cancers in various 
clinical trials (Carmeliet, 2005). 
1.10.1 HIF-1 complex 
The regulatory subunits of HIF which are involved in the hypoxia response 
pathway are HIF-1α and HIF-2α. Under normoxic conditions the HIF-1α and HIF-
2α subunits are short-lived due to prolyl hydroxylase (PHD) proteins mediating 
their degradation. HIF-1α and HIF-2α subunits interact with the von Hippel-
Lindau tumour suppressor protein (VHL) under normoxic conditions, in which 
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VHL targets HIF-1α and HIF-2α subunits for proteosomal degradation. This 
interaction though relies on the hydroxylation of critical HIF-1 proline residues by 
PHD enzymes (J. W. Lee, Bae, Jeong, Kim, & Kim, 2004). HIF-1α and HIF-2α 
can form heterodimers with HIF-1β (G. L. Wang, Jiang, Rue, & Semenza, 1995), 
inducing the transcription of genes which contain hypoxia-response elements in 
their promoters (Benest & Augustin, 2009). 
To date, VEGF-A and its receptors are the most well characterized signalling 
pathway in angiogenesis (Carmeliet, 2005). VEGF-A implements its biological 
effects by binding one of two receptor tyrosine kinases, VEGFR-1, and VEGFR-2 
(which is known to directly mediate the angiogenic signals of VEGF-A). The role 
of VEGFR-1 in mediating VEGF-A signals is more complex. VEGFR-1 may 
function as an anti-angiogenic receptor through sequestering VEGF-A, and thus 
preventing VEGF-A binding to VEGFR-2 (Fong, Rossant, Gertsenstein, & 
Breitman, 1995). However, other studies have demonstrated the importance of 
VEGFR-1 in haematopoiesis and recruitment of bone marrow-derived cells such 
as monocytes (Barleon, et al., 1996; Huusko, et al., 2010; Kearney, Kappas, 
Ellerstrom, DiPaola, & Bautch, 2004; Kerber, et al., 2008) 
1.10.2 Selenium and angiogenesis 
Importantly, Se compounds have been shown by various researchers to inhibit 
angiogenesis. In vitro experimentation using human DU 145 prostate cancer cells 
revealed that cellular and secreted VEGF levels were decreased in response to 
MSA in a dose-dependent manner (C. Jiang, et al., 2000). 
In vivo research has shown that Se compounds were able to reduce microvessel 
density in mammary carcinomas in rats injected with methylnitrosourea to initiate 
mammary carcinogenesis (C. Jiang, et al., 1999) indicating that Se may inhibit 
neovascularisation. Using Western blot analysis the same workers demonstrated 
that VEGF expression in some, but not all, mammary carcinomas exhibited a 
marked decrease in (C. Jiang, et al., 2000). Reduction in microvessel density in 
response to Se supplementation has also been observed in nude mice bearing 
MCF-7 breast cancer xenografts (Z. Li, et al., 2009). 
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Vasculature in solid tumours is characterized by its disordered arrangement as a 
result of excessive expression of angiogenic factors (Folkman, 1995). 
Interestingly Se supplementation has been shown to increase vessel maturation in 
(Bhattacharya, et al., 2008) resulting in improved tumour perfusion and thus 
improved tumour concentrations of irinotecan, and its active metabolite SN-38, 
(Yin, et al., 2006) as well as doxorubicin and capecitabine (Bhattacharya, et al., 
2009). The observed antiangiogenic effects of Se were demonstrated to be a result 
of VEGF depression mediated through inhibition of COX-2, HIF-1α and i-NOS 
due to stabilization of PHD enzymes (Y Rustum, unpublished results), which are 
typically inhibited under hypoxic conditions. These observations in part serve to 
explain the improved tumour response rates observed in these studies. 
1.11 Drug resistance 
Resistance to anticancer therapies can arise from a number of factors, either 
intrinsic, or acquired by malignant cells during treatment. The major mechanism 
responsible for acquired drug resistance to a broad variety of CT agents is the 
expression of multi-drug transporters (Gottesman, 2002). This is an energy-
dependent mechanism that detects the presence of, and enhances the ejection of, 
drugs out of the cell (Gottesman, 2002). But other mechanisms that involve 
insensitivity towards drug-induced apoptosis, and cell-detoxifying mechanisms, 
also play a pivotal role in acquired drug resistance. 
Endogenous nucleophiles in the cytoplasm such as glutathione (GSH) have been 
extensively investigated for their role in the development of resistance to 
anticancer treatments (Biaglow, et al., 1989; Bump & Brown, 1990; Coleman, 
Bump, & Kramer, 1988; Mitchell & Russo, 1987; Tew, 1994). In ovarian cancer 
xenograft-bearing mice, Caffrey & Frenkel (2000a) demonstrated that 
pretreatment with SLM or selenite prevented an increase in intracellular 
glutathione levels in response to cisplatin or melphalan. Using the same model the 
authors demonstrated that this strategy could prevent resistance developing to 
cisplatin, carboplatin or melphalan (Caffrey & Frenkel, 1998, 2000a, 2000b; 
Frenkel & Caffrey, 2001). UPR stress modulators have also been linked to CT 
resistance. Enhanced levels of GRP78 have been demonstrated to be involved 
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with resistance to various types of anticancer therapies (J. Li & Lee, 2006), 
whereas, reduction in GRP78 levels has been shown to increase the sensitivity of 
malignant cells to treatment (Rahmani, et al., ; Y. Wang, et al., 2008). 
1.12 Objectives of this thesis 
The overall objective of this thesis was to conduct an analysis of the biological 
characteristics of the differential impact of Se on malignant (THP-1 cells) and 
non-malignant cells (PBMC) in humans, with and without CT and RT. This 
investigation aimed to provide insights into the biological markers that may be 
informative in clinical trials using Se compounds to modulate the efficacy and 
toxicity of CT and/or RT.  
In order to investigate this, the biological effects of Se, cisplatin and RT were 
evaluated in vitro in cell culture models, to provide a framework of which markers 
to investigate clinically. The information gathered from the in vitro studies was 
used in part to evaluate the pharmacodynamic studies in humans undergoing 
anticancer therapy with or without Se.  
Specific objectives are listed in each chapter. 
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Chapter 2  
General methods 
2.1 Isolation of peripheral blood mononuclear cells 
(PBMC) 
PBMC were isolated from buffy coats obtained from blood donations given by 
healthy individuals, and supplied by the NZ Blood branch at Waikato Hospital. In 
order to isolate the mononuclear cell fraction via density gradient centrifugation, 
buffy coats were diluted 1:10 with sterile phosphate buffer saline (PBS) pH 7.4. 
Subsequently, 3ml of the diluted buffy coat suspension was layered over an equal 
volume of Histopaque 
®
 (Sigma-Aldrich) in a 15 ml falcon tube (CELLSTAR
®
). 
The tube(s) were placed in a Heraeus multifuge 1 S-R centrifuge and spun at 450 
x g for 30 min to separate out the component of the buffy coat.  Using a sterile 
transfer pipette the top layer was removed to just above the interphase which 
contained the PBMC. Using a new sterile pipette the interphase was removed and 
placed in a new 15 ml falcon tube. 10 ml of sterile PBS pH 7.4 was then gently 
added and gently mixed with the PBMC. The tube(s) were then placed back in the 
Heraeus multifuge and centrifuged for 10 minutes at 250 x g in order to wash the 
cells of contaminating platelets. The solution was carefully tipped off taking care 
not to disturb the pellet. The pellet was then resuspended in 5ml of sterile PBS pH 
7.4 and centrifuged as before. After a total of 3 washes the pellet was resuspended 
in 2 ml of RPMI-1640 culture media supplemented with 10% foetal calf serum, 
1% penicillin (10,000 units/ml) and streptomycin (10,000 µg/ml). 
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2.2 Measurement of cell concentration 
Cell concentration was measured using an Axiostar plus microscope and a 
haemocytometer. The haemocytometer was cleaned with 70% ethanol and 
allowed to dry. The shoulders of the haemocytometer were moistened and the 
cover slip affixed gently using small circular motions. The cover slip was 
considered properly affixed if Newton’s rings could be observed; this ensured the 
correct depths of the chamber. A 100 µl aliquot of the cell suspension in the 
culture media was transferred to a 1.7 ml Eppendorf tube and diluted 1:10 with 
sterile PBS pH 7.4. A 100 µl aliquot of this diluted suspension was then 
transferred to a new 1.7 ml tube and mixed gently with 100 µl of 0.4% (w/v) 
trypan blue solution and allowed to sit for 2 minutes. The cell suspension was 
gently mixed again, then using a pipette an aliquot of the cell suspension 
containing the trypan blue was drawn up and used to fill up the haemocytometer 
by resting the tip at the edge of the chambers and allowing capillary action to 
draw in the sample. The pipette was re-filled and the procedure performed again 
with the second chamber. 
 
The dimensions of the haemocytometer are as follows: 
 
Dimensions Area Volume at 0.1 mm depth 
1 x 1 mm 1 mm
2
 100 nl 
0.25 x 0.25 mm 0.0625 mm
2
 6.25 nl 
0.25 x 0.20 mm 0.05 mm
2
 5 nl 
0.20 x 0.20 mm 0.04 mm
2
 4 nl 
0.05 x 0.05 mm 0.0025 mm
2
 0.25 nl 
 
Using an Axiostar Plus light microscope the gridlines of the set of squares with a 
volume of 6.25 nl were focused upon using a 10X objective lens. These squares 
correspond to a set of 16 corner squares which measure a total volume of 100 nl 
when all are counted. In both chambers the 4 corners were used giving a total of 
128 6.25 nl squares or a volume of 800 nl. Using a tally counter, cells which were 
positioned within squares or on the bottom and right hand boundaries, and were 
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not stained blue by trypan blue, were counted. Cells which were stained were 
counted separately for viability. The number of cells in the 16 squares is 
equivalent to the number of cells x 10
4
/ml. Therefore, to obtain a count of cells, 
the total number of cells in 8 corner squares was calculated according to the 
following equation: 
  
 
 
This accounts for both dilution steps employed when preparing the sample to be 
counted. 
 
2.3 Trypan blue cell viability 
Trypan blue is used as a measure of cell viability. If cells have lost their 
membrane integrity trypan blue can permeate the cell causing the cytoplasm to be 
stained dark blue. These cells are assumed to be unviable and considered dead. 
Cells that were faintly or strongly stained blue were counted as dead cells and 
were counted in the same method as live cells. To calculate the viability of cells 
the following equation was used: 
 
 
 
 
2.4 Media preparation and PBMC culture conditions 
RPMI-1640 Medium was prepared as described by the manufacturers. All media 
was filter-sterilized with 0.22 µm filters. Foetal bovine serum was heat-inactivated 
by incubation at 56 C for 30 minutes. After isolation, PBMC were diluted to an 
appropriate density for particular experiments and cultured at 37 C in 5% CO2 in 
sterile greiner culture plates. 
Total cells counted 
4 
( ) X 10 = cells/ml x 104 
= percentage viability  ( ) 
Unstained cells 
Total cells X 100 
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2.5 THP-1 culture 
Cells were maintained in the aforementioned RPMI-1640 culture media 
supplemented with 10% foetal calf serum, 1% penicillin (10,000 units/ml) and 
streptomycin (10,000 µg/ml). The passage number of the cells since their original 
isolation was unknown, however, for experiments carried out, only cells passaged 
no more than 10 times were used in experiments. Cells were maintained at 37  C 
in a greiner 40 ml airtight culture flask. As recommended by the website, cells 
were maintained at a density below the 9 x 10
6
 cells/ml, which equated to sub-
culturing every two or three days. Cells were passaged by adding approximately 
six ml of fresh media (at 37  C) to approximately one ml of cell suspension. For 
experimentation, cells were aliquoted at appropriate densities into sterile greiner 
culture plates and cultured at 37 C in 5% CO2. 
2.6 Comet assay 
The single cell gel electrophoresis assay, otherwise known as the comet assay 
because of the appearance of a “head” with a “tail” of DNA fragments, was first 
described by Ostling and Johanson in 1984 and later adapted by Singh et al (1988) 
to include an alkaline step, which is the method used here. Preparation of fresh 
blood slides was carried out by topping a pre-agarose-coated slide (1% normal 
melting point in MQ water) prepared the day before, with a suspension of 5 µl of 
blood in 75 µl of 0.5% low melting point agarose in PBS pH 7.4. A 20 mm x 40 
mm coverslip was placed gently on top, and slides are kept at 4˚C for 10 minutes 
to allow the gel to solidify. After gels were set, the coverslips were gently 
removed.  
The gels were then lysed at 4˚C in a solution containing 1% Triton X-100, 10% 
DMSO, 2.5 M  NaCl, 100 mM EDTA, and 10 mM Tris (pH 10.0) for four hours. 
The resulting “nucleoid” was subsequently denatured for 20 min in an alkaline 
buffer [300mM NaOH and 1mM EDTA (pH > 13)] and electrophoresed using an 
Owl separation systems gel rig powered by Lightning Volt™ OSP-250L power 
supply for 20 min at 25 V and 300 mA in the same buffer. 
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After electrophoresis, slides were rinsed with distilled water before staining with 
SYBR Gold. 300 µl of SYBR Gold (1/10,000) was pipetted directly onto the 
slides and incubated for 10 minutes. The slides were then rinsed with distilled 
water to remove excess stain. Comets were examined by using Axiostar plus 
microscope, scoring 50 comet images from each slide and assessing DNA damage 
via the five classes of comets (0-4) described by Collins (2004). Slides were 
prepared in duplicate giving a total of 100 comets per sample (total score range of 
0-400).  
2.7 ER stress response markers  
Quantification of intracellular proteins that are markers of the ER stress response 
pathway (GRP78, phosphorylated elF2α, CHOP, spliced XBP1 and caspase-8) 
required a number of steps: firstly, protein isolation from PBMC derived from 
buffy coats or trial patient blood samples, or from cultured THP-1 cells; secondly, 
protein quantification from the cell lysates; thirdly, separation of protein lysates 
by gel electrophoresis; and fourthly, western blotting for the proteins of interest.  
Each of these steps is described below. 
2.7.1 Protein isolation from cell culture 
Total cell protein was isolated by lysing cells using RIPA (50 mM Tris pH 7.4, 
150 mM NaCl, 1% Triton-X-100, 1% Na-deoxycholate, 0.1% SDS, 1 mM EDTA, 
phosphatase inhibitors (PhosSTOP purchased from Roche, catalogue number: 04 
906 845 001), protease cocktail inhibitors (Purchased from Roche, catalogue 
number: 11 836 170 001), and 1 mM phenylmethanesulfonylfluoride (added just 
prior to lysis)), followed by centrifugation to remove cellular debris. Cells from 
each experiment were transferred from culture plates into 1.7ml tubes and 
sedimented with an Eppendorf centrifuge (5415 R) at 4  C for 10 minutes at 
1600rpm. The supernatant was pipetted off using a transfer pipette and cells were 
washed by resuspended the cell pellet in sterile PBS pH 7.4.  This procedure was 
repeated to ensure cells were properly washed. The cells were pelleted once more 
and resuspended in 150ul of RIPA buffer and vortexed for approximately 5 
seconds before being put on ice. Samples were allowed to lyse in ice for 30 
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minutes. Following lysis, lysates were centrifuged at 13,200 rpm for 10 minutes at 
4  C. Finally, the supernatants were transferred to a new 1.7ml tube and stored at – 
80  C until further analysis. 
2.7.2 Protein quantification from cell lysates 
Protein concentration was estimated using a modification of the Biuret assay. The 
bicinchoninic acid (BCA) assay was purchased from Thermo Scientific Pierce 
(catalogue number 23227) and stored at room temperature. This method utilizes 
the reduction of Cu
2+
 ions to Cu
1+
 by protein in an alkaline medium. Cu
1+
 ions are 
detected by the BCA reagent, forming a purple-coloured reaction that is 
spectrophotometrically detected at 562 nm. Standards containing bovine serum 
albumin were prepared at various concentrations in RIPA buffer and stored at -20 
 C until required. The BCA working reagent was prepared by combining 5 ml of 
BCA reagent A (Product number 23227) with 100 µl of BCA reagent B (4% 
cupric sulfate).  25 µl of standards and unknown samples were aliquoted into 0.6 
ml tubes and 200 µl of the working reagent added to each tube. Tubes were then 
incubated at 37  C for 20 minutes before being placed on ice. The OD562 was 
measured by aliquoting 2 µl of standard, or sample, onto the pedestal of a 
NanoDrop ND-1000 Spectrophotometer. Standards were measured first in 
triplicate to prepare a standard curve. Sample values were then measured in 
triplicate, and protein concentrations calculated using the prepared standard curve. 
2.7.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Denaturing polyacrylamide gel electrophoresis was performed for the separation 
of whole cell proteins lysates using a Hoefer mighty small SE250/SE260 gel rig. 
The procedure consists of three main stages: gel preparation, sample preparation 
and electrophoresis. The glass plates and spacers were cleaned with tap water, 
wiped dry with paper towels, and then cleaned again with 70% ethanol. Prepared 
plates were placed in a Hoefer five gel caster. Gels were prepared according to the 
appropriate composition shown in Table 2. Ammonium persulfate and TEMED 
(N, N,N,N’,N’-tetramethyl-ethylenediamine) were not added until immediately 
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before casting the gel. The separating gel was prepared in a 50 ml falcon tube 
(CELLSTAR
®
) then poured immediately into the five gel caster and overlaid with 
a thin layer of isopropanol. The gels were allowed to polymerise before pouring 
off the isopropanol and carefully drying off any remaining liquid on top of the 
gels with filter paper (Whatman No. 1). The stacking gel was then poured and 
combs (10 tooth) were put in place. The stacking gels were left to polymerise with 
a wet paper towel covering the top in order to prevent the gels from drying out. 
The apparatus was then dismantled and gels were wrapped with a wet paper towel 
and stored in zip lock plastic bag at 4   C for no longer than 4 weeks. 
Table 2: Composition of stacking and separating gels 
Reagent Concentration Volume* 
  Stacking Separating Stacking Separating 
37:1 Acrylamide:bis (22%) 4% 10% 1.98 ml 20.4 ml 
0.5M Tris HCl pH 6.8   3.75 ml n/a 
3M Tris HCl pH 8.8   n/a 6 ml 
10 % SDS (w/v)   150 µl 450 µl 
TEMED   15 µl 45 µl 
10 % APS (w/v)   150 µl 450 µl 
H2O    9 ml 17.7 ml 
*Sufficient to prepare 5 gels 
 
 
When required, gels were unwrapped and clamped to a Hoefer mighty small II 
(SE250/SE260) gel electrophoresis unit. The comb was removed and wells 
washed to remove any unpolymerised acrylamide out of the wells with MQ water 
using a syringe with an 18 gauge hypodermic needle. The buffer chambers were 
filled to the appropriate levels with SDS running buffer (25 mM Tris HCl, 192 
mM glycine, 0.1% SDS). The prepared samples were loaded with a 20ul pipette. 
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2.7.4 Western blotting 
To detect the presence and expression patterns of proteins involved in ER stress 
responses, gels were western blotted. Western blotting consists of three main 
procedures: protein transfer, antibody binding, and immunodetection. 
2.7.4.1 Transfer 
Proteins were electrophorectically transferred with either a nitrocellulose, or 
polyvinylidene fluoride membrane, using a fully submerged Biorad Mini-Trans-
Blot® blotting apparatus. The arrangement of the blot is illustrated in Figure 4. 
The membrane, and 4 pieces of 3MM filter paper were cut slightly bigger that the 
gel to ensure effective protein transfer. The sandwich was assembled as in Figure 
4 and transferred to the Biorad Mini-Trans-Blot® tank, along with an ice 
container and stirrer magnet. Transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol, 0.01% SDS) was added so the membrane was fully submerged and run 
for 1 hour at 100 V with constant stirring.  
Figure 4: Arrangements of components used in western blotting 
2.7.4.2 Antibody binding 
After the proteins were transferred to the membrane the blotting apparatus was 
carefully disassembled and transfer efficiency checked by ponceau (0.2% 
ponceau, 1% acetic acid) staining for 5 minutes. The following procedure is 
summarized in Table 3. The membrane was rinsed with distilled water and 
transferred to a new container with approximately 20ml of BLOTTO (10% skim 
milk in TBS-T) to be blocked for one hour at room temperature. Once the 
Black Perspex 
Clear Perspex 
Filter paper x2 
Filter paper x2 
Sponge 
Sponge 
Membrane 
Gel 
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membrane was blocked the membrane was transferred onto a 2 ml drop of 
primary antibody (appropriate dilution in BLOTTO) and incubated for one hour as 
illustrated in Figure 5. 
Table 3: Procedure for immunoblotting 
1
 TBS-T (Tris buffered saline-Tween 20) contains 20 mM Tris HCl pH 7.6, 150 mM sodium 
chloride, was diluted from a 10x stock solution and and 0.01 % Tween 20 (v/v) added last. 
 
Following the primary incubation, the membrane was washed vigorously in TBS-
T pH 7.4 for 10 minutes. This was repeated three times with fresh changes of 
TBS-T pH 7.4. The membrane was then carefully transferred onto a 2 ml drop of 
secondary antibody (appropriate dilution in BLOTTO), incubated, and washed as 
before. 
Step Solution 
Volume 
(ml) 
Duration 
Block 10% (w/v) skim milk powder in 
TBS-T
1
 (BLOTTO) 
30 ml 60 minutes 
1  Ab Binding Diluted antibody (rabbit anti-
human) in BLOTTO  
2 ml 60 minutes 
Wash  Three changes of TBS-T 20 ml 10 minutes 
each 
2  Ab Binding Diluted antibody (goat anti-
rabbit) in BLOTTO 
2 ml 60 minutes 
Wash  Three changes of TBS-T 20 ml 10 minutes 
each 
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Figure 5: Antibody binding apparatus 
2.7.4.3 Immunodetection 
The secondary antibody was detected using SuperSignal® West Femto Maximum 
Sensitivity Substrate (Product number 34095) purchased from ThermoScientific. 
SuperSignal® immunodetection was carried out according to the manufacturer’s 
directions. The membrane was transferred protein-side up onto a glass plate. 500 
µl of detection solution 1 was combined with 500 µl of detection solution 2 plus 
1ml water, and poured over the membrane so that it was completely covered. The 
membrane was incubated at room temperature without agitation for one minute. 
Excess detection solution was removed using a pipette, and an OHT sheet placed 
over the membrane. The glass plate-membrane-OHT sandwich was exposed for 
an appropriate amount of time using a FUJIFILM Intelligent dark box II LAS-
1000 system. 
2.8  Statistical analysis 
Comparison of the effects of each condition on malignant and normal cells were 
analysed using the student t test with Bonferroni correction for multiple analyses. 
Repeated measures ANOVA was used to evaluate changes of the means over time 
compared to baseline values in patient clinical samples. Two-tailed p < 0.05 was 
used as a threshold for statistical significance. 
Perspex box Drop of antibody (2ml) 
Glass plate 
Distilled water 
39 
 
Chapter 3  
In vitro investigations 
3.1 Introduction 
The dose-limiting toxicities of many current anticancer therapies treatments 
demonstrates the pressing importance of finding new agents that can ameliorate 
these toxicities and make treatments more tolerable, without compromising their 
effectiveness. Amifostine has been the most widely-investigated agent, but has 
had mixed and very limited success in clinical trials (Movsas, et al., 2005). Even 
more desirable would be compounds that both reduce normal tissue toxicity while 
enhancing the efficacy of anticancer therapies. Preclinical work has demonstrated 
that Se compounds act as multi-targeted modulators of the efficacy and toxicity of 
CT, resulting in improved tumour response rates and reduced organ-specific 
toxicity (S. Cao, F. A. Durrani, & Y. M. Rustum, 2004; M. Fakih, Cao, Durrani, 
& Rustum, 2005; Francescato, et al., 2001). Some aspects of these findings have 
been replicated in clinical trials with Se compounds, described in section  1.6.2, 
that suggest that they can both ameliorate the toxicity of CT and RT while 
enhancing treatment efficacy, though definitive clinical assessments of this have 
not yet been made.  
Clinical trials, however, are expensive to run and answer a relatively limited 
number of questions so it is preferable to evaluate the mechanisms of action of Se 
using preclinical models wherever possible, as long as they are informative to the 
clinical situation. This approach was taken to help inform the analysis of patient 
samples taken in the course of the clinical trial described in Chapter 4, where 
patients with head and neck squamous cell carcinoma (HNSCC) were treated with 
a radical course of cisplatin and RT and were randomised to receive either SLM 
or placebo for 11 weeks, starting a week prior to treatment. Specifically, what 
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changes in PBMC taken at periodic intervals from these patients could be 
expected? Furthermore, could an appropriate in vitro model be established in 
which to replicate some of the intended analyses in PBMC as well as in malignant 
cells, in order to explore the differential impact of Se on malignant and normal 
tissues? 
This chapter describes the approach undertaken to look at the effect of MSA, a Se 
compound that releases the active moiety methylselenol through non-enzymatic 
mechanisms in vitro, on cell viability, glutathione response, ER stress response 
and DNA damage and repair in vitro. 
3.1.1 Cell viability 
While the impact of Se on malignant cells can be readily studied in vitro with any 
number of malignant cell lines, it is more challenging to evaluate their effect on 
equivalent normal cells. A possible solution arose from the observation in 2008 
that various aspects of the effects of Se on cells can be measured in human 
PBMC, both in vitro and in vivo (S Joel, unpublished observations). This offered 
the opportunity to compare the impact of Se compounds on normal and malignant 
cells in vitro by using fresh PBMC (derived from the buffy coats that are 
separated from red cells in blood donations) and malignant THP-1 human 
leukaemia cells. This in turn will help in investigating the biological impacts of 
high-dose Se supplementation in patients. 
3.1.2 Glutathione 
Cells posses a repertoire of enzymatic and non-enzymatic antioxidant defences. 
The various non-enzymatic defences include α-tocopherol (Vitamin E), ascorbic 
acid (Vitamin C), carotenoids, flavonoids and GSH, among others. Cellular redox 
homeostasis under normal conditions involves a balance between the intracellular 
levels and activities of these various antioxidants. GSH is the most abundant 
nonprotein cellular thiol (Arrick & Nathan, 1984). It is involved in the 
maintenance of the cellular redox state, removal of hydroperoxides, and the 
detoxification of many xenobiotics (Arrick & Nathan, 1984) It is present inside 
cells mainly in the reduced form (90 – 95% of total GSH). Intracellular GSH can 
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serve as an indicator of cellular health, and a cells ability to resist toxic challenges 
(Arrick & Nathan, 1984). 
As discussed in section  1.11, acquired resistance against CT and RT significantly 
impairs the efficacy of current anticancer therapies. Increased intracellular GSH 
concentrations have been implicated in mediating resistance to both CT and RT. 
3.1.3 Comet assay 
The comet assay was used to assess the genotoxicity of MSA and cisplatin in 
PBMC. In addition, given that cisplatin is known to cross-link DNA strands and 
thus reduce RT-induced DNA fragmentation as assessed by comet assay an 
evaluation was made of whether cisplatin reduces the formation of a comet in 
vitro by the DNA-damaging agent H2O2. 
3.1.4 ER stress response 
ER stress is an important mechanism in cancer therapeutics, as demonstrated by 
the proteosome inhibitor bortezomib, which causes accumulation of aberrantly-
folded proteins within the cell and induces ER stress, and thus apoptosis through 
induction of the unfolded protein response (UPR) (Szegezdi, et al., 2006). 
However, while inducing the UPR has been reported to sensitise malignant cells 
to cytotoxic drugs (C. C. Jiang, et al., 2007), others have reported ER stress 
provides resistance (Ranganathan, Zhang, Adam, & Aguirre-Ghiso, 2006). It has 
become clear that cell type and drug action can determine the differential response 
to ER stress. 
Se supplementation has been shown to act through targeting mediators of the ER 
stress signal (Wu, et al., 2005), resulting in an increase in apoptosis. Additionally, 
Se appears to selectively sensitize tumour cells to a number of therapeutic drugs 
while at the same time increasing the resistance towards these drugs in normal 
cells (S. S. Cao, et al., 2004). This differential effect of Se administration on ER 
stress could, in part, account for the enhanced therapeutic efficacy of 
chemotherapy with Se.  
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The UPR can be activated by three different transmembrane receptors; PERK, 
IRE1, and ATF6. This study investigated the activation of UPR targets in 
response to MSA treatment in PBMC and THP-1 cells to evaluate whether MSA 
induces differential responses in the two cells types, i.e. pro-survival markers in 
PBMC and pro-apoptotic markers in THP-1 cells 
3.1.5 Objectives 
The overall objective of this chapter was to evaluate to evaluate whether PBMC 
and THP-1 cells could successfully be used as an in vitro model to determine 
differential effects of Se on normal and malignant mononuclear cells. The specific 
objectives were: 
 
1. to evaluate the comparative effects of MSA on viability of PBMC and 
THP-1 cells and whether it differentially modulated the cytotoxicity of 
clinically-relevant concentrations of cisplatin or RT in these two cell 
populations; 
2. to assess whether total intracellular GSH levels changed in response to 
MSA treatment in PBMC and THP-1 cells; 
3. to investigate whether MSA alone or in combination with cisplatin and 
RT modified DNA damage and repair in these cells as assessed by the 
comet assay; and 
4. to evaluate changes in ER stress response markers to MSA. 
3.2 Methods 
Methodology for ER stress response markers is described in section  2.7. 
Additional methodology is described below. 
3.2.1 Cell viability  
To study the cytotoxic effects of MSA or cisplatin on malignant and non-
malignant cells, PBMC and THP-1 cells were incubated for 24 hrs in cell culture 
media as described in section  2.4. Cells were incubated with 0, 2.5, or 5 µM MSA 
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for 24 hours. In order to establish the cytotoxic effects, cell viability was 
measured using the tetrazolium salt MTT assay. 
The differential response to cisplatin was investigated using mononuclear cells 
that differ in their phenotype (non-malignant vs. malignant). PBMC and THP-1 
cells were incubated for 24 hours with two concentrations of cisplatin, and cell 
viability assessed using the MTT assay. The two concentrations of cisplatin used 
in this investigation were 8.33 µM, which can be considered clinically relevant 
(Johnsson, Bjork, Schutz, & Skarby, 1998; Johnsson, Hoglund, Grubb, & 
CavallinStahl, 1996), and a higher concentration of 20 µM. 
When it became apparent that there was no difference in cell viability between the 
two cisplatin concentrations, subsequent experiments were carried out using only 
the lower, clinically-relevant, cisplatin concentration. In order to assess whether 
MSA enhanced the cytotoxicity of cisplatin, cells were pretreated with 0, 2.5 and 
5 µM of MSA for 6 hours before cisplatin was added. 
In order to assess whether THP-1 radiosensitivity was modulated by cisplatin and 
MSA, THP-1 cells were incubated for 24 hours with 8.33 µM cisplatin, and 2.5 or 
5 µM MSA. Cells were irradiated with 10 Gy and viability assessed immediately. 
3.2.1.1 MTT assay 
Mosmann (1983) first described the conversion of a tetrazolium salt to the 
coloured product formazan as a measure of cell viability. The MTT (methyl-
thiazol-tetrazolium) assay was used in order to assess the impact of various 
treatments on cell viability in THP-1 and PBMC cells. MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) was purchased from AppliChem 
(CAS-No: 298-93-1) and stored at 4 ° C. When required, it was dissolved in 
sterile PBS pH 7.4 at a concentration of 5 mg/ml, at room temperature. This 
solution was further sterilized by filtering through a 0.4 µm Whatman filter and 
stored in a dark bottle at 4 ° C for no longer than one month.  
Cells were incubated in sterile greiner bio-one 24 well cell culture plates. 
Approximately 6 x 10
4
 THP-1 cells were incubated in a volume of 1 ml with or 
without MSA or cisplatin. PBMC were incubated under the same conditions 
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except at a cell density of approximately 2 x 10
5
. After 24 hours, 250 µl of the 5 
mg/ml MTT stock solution was added to each well (final concentration 1mg/ml) 
and incubated for a further two hours. Following this two hour incubation, 1ml of 
extraction buffer (20% SDS (w/v), 50% dimethylformamide (v/v) pH 4.7) was 
added in order to lyse the cells, and solubilise the formazan crystals formed during 
the incubation with MTT. After an overnight incubation at 37  C the optical 
densities were measured at 600 nm using a BMG Labtech FLUOstar OPTIMA 
plate reader, using the extraction buffer as a blank. It should be noted that the 
formazan production is proportional to the number of live cells. 
3.2.2 Glutathione assay  
The glutathione assay kit was purchased from Sigma-Aldrich (Catalog Number 
CS0260) and stored at 4  C while not being used. The assay was carried out 
according to the manufacturer’s directions. The assay measures total GSH by 
spectrophotometrically measuring the optical density of the yellow product 5-thio-
2-nitrobenzoic acid (TNB) at 412 nm. TNB is formed by the reduction of 5,5-
dithiobis(2-nitrobenzoic acid) (DTNB). GSH reduces DTNB to TNB and the 
oxidized GSH (GSSG) formed is recycled by glutathione reductase and NADPH. 
Thus, using a kinetic assay, the total catalytic amounts of GSH can be measured. 
PBMC and THP-1 cells were incubated with 0, 2.5 and 5 µM of MSA for six 
hours. Cells were then harvested and total GSH prepared as described below. 
Cells were cultured (see section  2.4) for six hours before being transferred to 1.7 
ml Eppendorf tubes and pelleted at 1600 rpm for eight minutes. Cells were 
washed twice in sterile PBS, pH 7.4, before being pelleted a final time. Using a 
five percent 5-sulfosalicylic acid solution (SSA), a volume approximately three 
times that of the pellet was added into the same tube in order to deproteinize the 
sample. This preparation was vortexed and the suspension frozen and thawed 
twice (using liquid nitrogen to freeze and a 37 ºC bath to thaw). Following this, 
the suspension was placed at 4  C for five minutes and then centrifuged at 10,000 x 
g for 10 minutes. After centrifugation the supernatant was removed with a pipette 
and aliquoted into a new 1.7 ml tube. The total volume of supernatant was 
measured for the calculation of total GSH. 
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Table 4: Glutathione reaction scheme 
 Mix and incubate 5 minutes Start 
Sample measured Sample 
volume 
5% SSA Working 
mixture 
NADPH  
(0.16 mg/ml) 
Reagent blank n/a 10 µl 150 µl 50 µl 
Standard curve (various 
concentrations) 
10 µl n/a 150 µl 50 µl 
Unknown sample X µl 10 µl 150 µl 50 µl 
 
 
Using a 96-well greiner plate, the total GSH level was measured following the 
reaction scheme outlined in Table 4. The final concentration of the components in 
the reaction mixture were 95 mM potassium phosphate buffer, pH 7.0, 0.95 mM 
EDTA, 0.038 mg/ml (48 mM) NADPH, 0.031 mg/ml DTNB, 0.115 units/ml 
glutathione reductase, and 0.24% 5-sulfosalicylic acid. The BMG Labtech 
FLUOstar OPTIMA plate reader was set to 412 nm with kinetic read at 1 minute 
intervals for 5 minutes. Following the assay the values of the GSH standards were 
used to construct a standard curve. This was used to calculate the ∆A412/min 
equivalent to 1 nmole of reduced glutathione per well. The following equation 
was then used to calculate the nmoles of GSH in the unknown sample using the 
following equation: 
 
 
 
 
 
where ∆A412/min (sample) = slope generated by sample (after subtracting the 
values generated by the blank reaction); ∆A412/min (1 nmole) = slope calculated 
from standard curve for 1 nmole of GSH; dilution = dilution factor of original 
sample; volume = volume of sample in the reaction in ml. 
∆A412/min (sample) x dilution 
∆A412/min (1 nmole) x volume 
nmoles of GSH per 
ml of sample 
= 
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3.2.3 Comet assay 
The general methodology for the comet assay is described in section  2.6. The 
specific adaptation for this in vitro work is described here. 
5 x 10
5
 PBMC cells were incubated with 0, 2.5, or 5 µM MSA or 20 µM cisplatin 
for 24 hours in 1 ml of cell culture media (Chapter 2) in sterile greiner 24-well 
culture plates. After incubation cells were transferred to a 1.7 ml tube, and 
pelleted by centrifugation at 1600 rpm for 8 minutes at 4 C. The supernatant was 
removed and cells were washed by resuspending them in 500 µl of sterile PBS pH 
7.5. The cells were then pelleted by centrifugation at 1600 rpm for 8 minutes at 4 
C and washed again as before for a total of two washes. After the final wash step, 
PBMC were resuspended in 100 µl of sterile PBS pH 7.5. 10 µl of cell suspension 
(approximately 5 x 10
4
 cells) was mixed with 70 µl of 0.5% low melting point 
agarose in PBS pH 7.4 and the preparation of slides carried out as described in 
section  2.6.  
In order to assess whether cisplatin reduces the formation of a comet by H2O2 in 
vitro, PBMC conditioned as above with either media alone or cisplatin were 
exposed to H2O2 by immersing prepared slides in ice-cold 100 µM H2O2 for five 
minutes. Slides were then washed by immersing in ice-cold PBS pH 7.4 for five 
minutes. These steps were carried out on ice to ensure DNA repair was 
minimized. The comet assay methodology was then continued as described in 
section  2.6. Comparator slides were not exposed to H2O2. 
3.2.4 ER stress response 
In order to assess the in vitro effects of MSA on PBMC and THP-1 cells 
immunoblotting was carried out to asses protein levels of known UPR targets, as 
well as caspase-8. Both PBMC and THP-1 cells were plated at a cells density of 6 
x 10
5
 cells/ml in a total volume of 2 ml, in sterile greiner 6-well culture plates and 
incubated for six hours in the presence of 0, 2.5 and 5 µM MSA. The general 
methodology of protein isolation and immunoblotting is described in  2.7. Protein 
lysates were then probed for the pro-survival UPR proteins phospho-eIF2α and 
spliced XBP1, as well the pro-apoptotic UPR mediator CHOP and the pro-
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apoptotic caspase-8. BLOTTO was used to block membranes and dilute 
antibodies in all westerns except phospho-eIF2α. Extremely high background was 
encountered when using BLOTTO with this antibody. Thus 3 % (w/v) bovine 
serum albumin was used to dilute the antibody to a working concentration, and 
block the membrane. 
3.3 Results 
3.3.1 Cell Viability 
3.3.1.1 PBMC viability 
Results of PBMC are generated from three separate buffy coats, each evaluated in 
triplicate. Figure 6 shows that PBMC viability was not significantly affected in 
response to the different concentrations of MSA used in this study.  
Figure 6: PBMC viability in response to 24hr MSA treatment (n=9).  
Similarly, Figure 7 shows that concentrations of 8.33 or 20 µM cisplatin did not 
affect PBMC viability. Nor did pretreatment of PBMC with MSA for 6 hours 
before incubation with 8.33 µM cisplatin for 24 hours affect cell viability (Figure 
8). 
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Figure 7: PBMC viability in response to 24hr cisplatin treatment (n=9). 
Figure 8: Effects of 6hr MSA pretreatment on PBMC viability in response to 
24 hr treatment with 8.33 µM cisplatin (n=9). 
In order to assess whether MSA provided protection for PBMC against RT, 
PBMC were incubated with 8.33 μM cisplatin or 2.5 or 5 µM MSA and irradiated 
with 10 Gy. Cell viability was immediately assessed after irradiation using the 
MTT assay. As shown in Figure 9, there was no significant difference in PBMC 
viability in any of the treatments directly after irradiation. 
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Figure 9: PBMC viability after 10 Gy irradiation (n=6) 
 
3.3.1.2 THP-1 viability 
The cytotoxicity of MSA on the human monocytic leukaemia THP-1 cell line was 
assessed using the MTT assay.  Figure 10 shows that MSA reduced the viability 
of THP-1 cells in a concentration-dependent manner at 2.5 and 5 µM (p = 0.0026 
and 0.0001 respectively).  
 
Figure 10: THP-1 cell viability in response to 24hr MSA treatment (results 
are obtained from two experiments; n=6; ** p < 0.01, *** p <0.001) 
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Viability of THP-1 cells was also significantly reduced in response to 8.33 µM (p 
= 0.0005) and 20 µM (p = 0.0001) cisplatin. There was however no significant 
difference between 8.33 and 20 µM cisplatin on THP-1 cell viability (Figure 11). 
Figure 11: THP-1 cell viability in response to 24hr cisplatin treatment 
(results are obtained from two different buffy coats; n = 6, *** p <0.001). 
 
Pretreatment with MSA for 6 hours enhanced the cytotoxicity of a 24 hour 
incubation with cisplatin in this cell line: 2.5 and 5 µM MSA with 8.33 µM 
cisplatin significantly reduced THP-1 cell viability when compared with cisplatin 
alone (p = 0.0067 and 0.0041 respectively, Figure 12). 
Figure 13 shows that MSA increased radiosensitivity in a dose-dependent manner. 
MSA significantly affected THP-1 cell viability at both 2.5 µM (p = 0.0143) and 5 
µM (p = 0.003). In contrast, the addition of 8.33 µM cisplatin did not significantly 
reduce THP-1 cell viability compared to radiation alone. 
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Figure 12: Effects of 6hr MSA pretreatment on THP-1 cell viability in 
response to 24hr cisplatin treatment (results are obtained from two 
experiments; n = 6, ** p <0.01). 
 
Figure 13: THP-1 cell viability after 10 Gy irradiation (results are obtained 
from two different buffy coats; n = 6, * p < 0.05, *** p <0.001). 
 
 
3.3.2 Glutathione assay 
Total GSH level in THP-1 cells was reduced significantly in a concentration-
dependent manner as shown in Figure 14: 2.5 µM of MSA significantly reduced 
total GSH (p = 0.0050) as well as 5 µM of MSA ( p = < 0.0001). 
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Figure 14: THP-1 glutathione levels in response to 6hr MSA treatment 
(results are obtained from two experiments; n = 6, ** p < 0.01, ** p <0.001). 
A reversed impact of MSA on total GSH levels in non-malignant PBMC (as 
compared to malignant THP-1 cells) was observed (Figure 15), though again in a 
concentration-dependent manner:  2.5 µM of MSA significantly increased total 
GSH (p = 0.0080) as well as 5 µM of MSA (p = < 0.0001). 
Figure 15: PBMC glutathione levels in response to 6hr MSA treatment 
(results are obtained from three different buffy coats; n = 10, ** p < 0.01, ** 
p <0.001). 
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3.3.3 Comet assay 
The results are shown in Table 5. DNA damage was detectable in control PBMC 
at low levels and increased significantly with MSA 2.5 or 5 µM. H2O2 caused a 
greater degree of damage as expected but this was significantly reduced by 
cisplatin 20 µM (which modestly caused DNA damage in its own right). RT 10 
Gy, on the other hand, caused such profound damage to PBMC that all PBMC 
samples had a maximum score.  
Table 5.  Comet assay results in PBMC 
 
Treatment 
Comet score (mean ± SD) 
(max. 400) 
Control 7 ± 5.6 
100 µM H2O2 149 ± 7.5 
20 µM cisplatin 13 ± 4.1 
20 µM cisplatin +100 H2O2 75 ± 7.1 
2.5 µM MSA 17 ± 1.5 
5 µM MSA 41 ± 3.5 
RT 10 Gy 400 
 
3.3.4 ER stress response 
All experiments with PBMC obtained from buffy coats were carried out in 
duplicate using two separate buffy coats. THP-1 cell results are obtained from 
only one experiment. Results presented are representative of those experiments. 
Β-actin was used as a loading control in all westerns. Equal loading of protein into 
each well is demonstrated in Figure 16. 
54 
 
Figure 16: Loading control  
As shown in Figure 17, MSA induced XBP1 splicing in PBMC in a 
concentration-dependent fashion. While THP-1 cells expressed spliced XBP1 at 
baseline, treatment with MSA increased XBP1 splicing, though 2.5 µM MSA 
produced higher levels of spliced XBP1 than 5 µM. After six hours, phospho-
eIF2α was only slightly elevated in response to MSA treatment in both PBMC and 
THP-1 cells, though THP-1 cells exhibited higher levels of phospho-eIF2α at 
baseline compared to PBMC. 
Figure 17: ER stress pro-survival markers 
 
 
Expression of GRP78 was detected in both PBMC and THP-1 cells (Figure 17). 
In THP-1 cells it appears that GRP78 expression is unaltered in response to MSA 
treatment. Like phospho-eIF2α, GRP78 expression is elevated in the control. 
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GRP78 is upregulated in response to MSA in PBMC. Expression of GRP78 
appears to increase in a concentration-dependent manner as shown in Figure 17. 
CHOP was shown to be expressed in PBMC at baseline, and was unchanged in 
response to MSA treatment (Figure 18). CHOP expression was unable to be 
detected in THP-1 cells. Caspase-8 expression was not induced in PBMC treated 
with MSA. In contrast, caspase-8 was slightly upregulated in THP-1 cells treated 
with MSA after six hours. 
Figure 18: Pro-apoptotic markers 
3.4 Discussion 
3.4.1 Cell viability 
This investigation was undertaken to evaluate whether PBMC and THP-1 cells 
could be used as a model to determine differential effects of Se on malignant and 
normal mononuclear cells. This was confirmed: MSA had no impact on PBMC 
viability, while it significantly reduced THP-1 cell viability. In addition this study 
showed differential effects of cisplatin in these cells, with no effect on viability of 
PBMC viability over 24 hours but marked reduction in viability of THP-1 cells in 
a concentration-dependent manner.  
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Furthermore, MSA increased the cytotoxicity of both cisplatin and radiation 
treatments in these malignant cells while no such effects were observed in PBMC. 
These concentration-dependent effects of MSA occurred at physiologically-
relevant concentrations (Ip, et al., 2000). Given these effects of MSA on each 
cancer treatment, it would be interesting to see if it produced even better 
malignant cell kill when used in conjunction with both cisplatin and RT. 
These data are in agreement with work by Vadgama et al. (2000) who 
demonstrated therapeutic synergy when Se derived from yeast was used in 
combination with various chemotherapeutic drugs in several malignant cell lines. 
This study showed that Se enhanced cell growth inhibition of CT and increased 
apoptosis in various malignant cell-lines whereas the non-malignant breast cell-
line MCF-10 was insensitive to Se-induced growth inhibition and apoptosis 
induction.  
Similarly previous studies showed that Se compounds increased the 
radiosensitivity of malignant cells. Using clonogeneic survival assays,  Shin et al. 
(2007) showed that Se, in the form of SLM, enhanced the cytotoxicity of radiation 
on two malignant lung cell lines, while having little effect on normal diploid WI-
38 cells. These authors further showed that SLM reduced both mRNA and protein 
levels of epidermal growth factor and DNAPK, which are involved in cell survival 
signalling and the DNA damage response respectively. In contrast, SLM had no 
impact on the expression profile of these elements in the non-malignant cell line. 
PBMC from healthy blood donors were used during this study. Although no cell 
cycle assessment was undertaken, it can be largely assumed that isolated PBMC 
are post-mitotic in the G0 phase. That is, PBMC were not actively progressing 
through various phases of the cell cycle. Given the cytotoxicity of cisplatin is 
maximal at the end of the G1 phase, cells not progressing through the cell cycle 
could exhibit cellular resistance towards cisplatin (Gupta, et al., 2010). Using the 
MTT assay, PBMC were insensitive to MSA, cisplatin, and MSA + cisplatin 
treatments, as well as radiation. This resulted in no observed differences in cell 
viability between these treatments and controls (Figure 6,Figure 7,Figure 8 and 
Figure 9). However this is most likely due to the fact that PBMC were not actively 
dividing and senescent.  
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A number of studies investigating the impact of CT and RT on PBMC typically 
use a mitogen to activate cells into the cell cycle. Mitogens are chemical 
substances that trigger mitosis through signal transduction cascades involving 
mitogen-activated protein kinases. It would be recommended that further studies 
using PBMC specifically to investigate the cytotoxic effects and/or growth 
inhibitory effects of MSA, alone or in combination with radiation and 
chemotherapeutic drugs such as cisplatin, use a mitogen to activate mitosis. 
Irradiation can be lethal at all stages of the cell cycle, though cellular resistance 
toward RT has been demonstrated in cells which undergo growth arrest (Waldman 
et al. 1997). While no significant difference in PBMC viability to 10Gy RT was 
detected, this was assessed immediately following irradiation. This does not 
necessarily indicate that cells were not suffering from a lethal dose of RT or even 
undergoing apoptosis, just that no effect was evident at a very early stage (in 
contrast to the THP-1 cells). Therefore in further experiments cell viability should 
be measured at later time points after irradiation in order to provide greater 
insight. Again, the use of a mitogen would also be useful. 
There is a possibility that the observed difference between THP-1 cell\and PBMC 
viability is due to a different cell type (not just the difference in malignant and 
non-malignant phenotype). PBMC consist of lymphocytes, monocytes, and 
macrophages. Lymphocytes make up the majority of the population, with 
approximately 75% being T cells. THP-1 cells are an acute monocytic leukaemia 
cell line; therefore, in this study, the cell viability assays largely compared 
lymphocytes with monocytes, which could have had a significant impact on the 
response to MSA. Any future studies comparing the effects of MSA in PBMC and 
THP-1 cells would have to take this into account and perhaps aim to isolate 
monocytes preferentially from the buffy coats. 
3.4.2 Glutathione 
We investigated the change in total intracellular GSH in THP-1 cells and PBMC 
in response to MSA treatment in vitro. Interestingly, we observed differential 
effects of MSA in the two cell types: MSA decreased total GSH levels in THP-1 
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cells in a concentration-dependent manner, while in contrast MSA increased total 
GSH levels in PBMC, again in a concentration-dependent manner.  
Interestingly THP-1 cells had significantly higher amounts of intracellular GSH 
than PBMC in the absence of MSA (p < 0.0001) (Figure 14 Figure 15). Malignant 
cells have acquired mutations that cause cellular adaptations favouring survival 
and this is one of them. GSH reacts with chemotherapeutic drugs, including 
cisplatin, forming inactive species (Berners-Price & Kuchel, 1990; Pendyala, 
Creaven, Perez, Zdanowicz, & Raghavan, 1995) and elevated GSH levels in 
response to cisplatin exposure has been implicated in resistance to platinum-based 
therapies (Agarwal & Kaye, 2003). Furthermore, in the nucleus elevated GSH 
levels have been implicated in resistance through the maintenance of particular 
protein redox states that are necessary for DNA repair (Lai, Ozols, Young, & 
Hamilton, 1989; Valko, Rhodes, Moncol, Izakovic, & Mazur, 2006). Clinically 
glutathione S-transferase levels in head and neck cancer patients have been 
associated with failure to respond to platinum-based therapy (Nishimura, et al., 
1996). The cell cycle can be modulated by intracellular concentrations of GSH 
(Arrigo, 1999; Kern & Kehrer, 2005; Schafer & Buettner, 2001) and depletion of 
total intracellular GSH, causing the cellular environment to become more 
oxidized, has been associated with increased apoptosis and necrosis (Cai & Jones, 
1998; Evens, et al., 2004; Voehringer & Meyn, 2000). Given this, drugs that 
target redox systems of cells are proposed to be useful in chemoprevention and 
chemotherapeutics (Evens, et al., 2004). 
Section ‎3.3.1 showed that the MSA enhanced the reduction in THP-1 cell viability 
from cisplatin. Although no analysis of GSH changes in response to cisplatin 
alone was performed, nor of apoptosis, the reduction in GSH levels of THP-1 
cells due to MSA exposure could well be responsible for this observed synergy. 
That is, reduced GSH levels would sensitize the cell to cisplatin, thus increasing 
the therapeutic efficacy of treatment. This is in agreement with previous studies 
that have shown that Se compounds enhance the therapeutic activity of CT in 
malignant cells. Moreover, in response to MSA treatment and total GSH 
depletion, THP-1 cells may accumulate at particular phases of the cell cycle; this 
in turn could lead to enhanced sensitivity towards treatments. However no 
analysis of cell cycle was done in this study. Therefore it would be interesting to 
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investigate whether cells accumulate at particular phases of the cell cycle in 
response to MSA treatment, as well as whether intracellular levels of GSH change 
in response to cisplatin or RT alone, and the effect of MSA on these changes. 
The role of intracellular GSH in the cellular response to radiation has been 
evaluated in a number of studies. Radioprotection has been shown in vitro to be 
associated with increased levels of NPSH (Revesz & Bergstrand, 1963), while 
reduced GSH levels renders cells more sensitive to radiotherapy (Revesz, 
Bergstrand, & Modig, 1963). Radiation sensitivity of THP-1 cells was shown in 
section ‎3.3.1 to be enhanced by MSA in a concentration-dependent manner. Given 
these data, the reduction in intracellular GSH levels in THP-1 cells may account 
for this increased radiosensitivity. 
The corollary is that the demonstrated ability of MSA to increase GSH levels in 
PBMC could therefore provide a protective effect, and may mediate, at least in 
part, the observed ability of Se compounds to reduce the toxicity of CT and RT in 
normal tissues (Muecke, et al., 2010; Sieja & Talerczyk, 2004). Further studies 
investigating whether this increase in GSH provides a reduction in toxicity in 
normal cells would therefore be warranted. As mentioned in earlier, use of a 
mitogen to provide actively mitotic normal cells may help to elucidate whether the 
increase in GSH levels in response to MSA in PBMC is responsible for the 
protective effects against CT and RT, or whether it is the lack of cell proliferation 
is important. 
3.4.3 Comet assay 
Some species of Se have been shown to be genotoxic, therefore, the comet assay 
was used to assess if MSA was capable of inducing DNA damage in PBMC in 
vitro, which it did significantly in a concentration-dependent manner at 2.5 and 5 
µM of MSA. This is in contrast to the work carried out by Ip et al. (2000) that 
showed MSA did not induce DNA damage. Both this study and the study of Ip 
and colleagues used 24 hour cultures exposed to the same concentration of MSA 
and similar comet conditions. The only obvious difference is that this study used 
non-malignant PBMC, and Ip and colleagues used malignant TM2H and TM12 
cells. This may reflect that the genotoxicity of MSA is dependent on cell type. 
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In order to confirm that cisplatin did indeed reduce the formation of comets in 
PBMC under the experimental conditions used in this assay; PBMC were 
incubated with 20 µM cisplatin for 24 hours. As shown in Table 5 cisplatin does 
indeed reduce the formation of comets induced by H2O2. This is in agreement 
with previous studies which have shown that cisplatin reduces the formation of 
comets (Merk & Speit, 1999; Pfuhler & Wolf, 1996). The dose of RT used in this 
study was overwhelming in terms of DNA damage detection by the comet assay, 
and it would be interesting to evaluate the impact of smaller RT doses such as 2 
Gy, as used in the trial discussed in Chapter 4, on DNA damage to PBMC in vitro, 
and the ability of cisplatin to reduce the formation of comets in that setting.  
3.4.4 ER stress response 
MSA was shown to activate various UPR targets in both cell types (Figure 17 and 
Figure 18). The use of Se compounds, in particular MSA, has previously been 
shown to induce ER stress in a concentration- and time-dependent manner in a 
PC-3 human prostate cancer cell line (Wu, et al., 2005). The authors found that 
high concentrations of MSA induced pro-apoptotic ER stress-induced targets such 
as CHOP (GADD153). In contrast, low levels induced pro-survival proteins such 
as phosphorylated eukaryotic initiation factor-2 alpha (phospho-eIF2α) and 
glucose-regulated proteins 78 (GRP78) and 94 (GRP94). 
In this study XBP1 splicing was induced by MSA in a concentration-dependent 
manner in PBMC, while in THP-1 cells 2.5 µM MSA appeared to induce higher 
expression of spliced XBP1 compared to 5 µM (Figure 17). XBP1 mRNA is 
induced by activated ATF6 and spliced into a highly active and stable 
transcription factor by activated IRE1, though a significant induction of XBP1 
mRNA due to ATF6 was required to produce spliced XBP1 at a level sufficient 
for detection and transactivation (Yoshida et al. 2001). Furthermore, spliced 
XBP1 can keep activating transcription by autoregulating its own transcription as 
long as IRE1 is activated (Yoshida et al 2000). This study showed that spliced 
XBP1 was the dominant isoform in response to MSA in THP-1 cells (Figure 17). 
This is consistent with Yoshida et al. (2000) who showed only spliced XBP1 was 
detected at high levels in cell lysates in response to ER stress. Conversely, 
increased levels of unspliced XBP1 were observed in concert with increased 
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spliced XBP1 in PBMC (Figure 17). Treatment with 5 µM MSA induced higher 
levels of spliced XBP1 compared to baseline in PBMC than in THP-1 cells. This 
may reflect that 5 µM of MSA will afford PBMC a higher degree of survival 
against toxic challenges and further iterations of this experiment could be 
informative. 
Induction of phospho-eIF2α was also shown in both PBMC and THP-1 cells 
(Figure 17). Phospho-eIF2α has been previously shown to be a pro-survival 
mechanism as it lessens the burden of aberrantly-folded proteins through 
translation inhibition. Phospho-eIF2α was already induced in control THP-1 cells, 
and only slightly upregulated in response to MSA. This baseline expression of 
phospho-eIF2α may reflect the malignant phenotype and survival strategy of 
THP-1 cells. However, since this experiment was only carried out once, this may 
reflect that these cells were stressed before the experiment started, that is, the 
levels of UPR targets in THP-1 cells were already upregulated and may reflect 
previous stresses, not induced by MSA. This experiment should be conducted 
again in order to confirm either way.  
CHOP expression in PBMC was present in controls and MSA did not induce 
higher levels of expression (Figure 18). In contrast, CHOP was unable to be 
detected in THP-1 cells at the concentrations of MSA used. Wu et al. (2005) 
showed that CHOP induction was severely attenuated in GRP78 overexpressing 
cells (GRP78 allows cells to cope with ER stress). In the THP-1 cells GRP78 was 
upregulated in control conditions (Figure 17). Therefore, in this instance, the 
inability of MSA to induce CHOP expression may be the result of THP-1 cells 
expressing elevated levels of GRP78. This is in agreement with previous studies 
that have demonstrated resistance to various types of anticancer drugs in cells 
expressing enhanced levels of GRP78 (J. Li & Lee, 2006), and reducing GRP78 
expression results in increased sensitivity towards treatments (Rahmani, et al., ; Y. 
Wang, et al., 2008). GRP78 was upregulated in response to MSA in PBMC. 
Therefore, PBMC exposed to MSA should have enhanced resistance to toxic 
challenges since GRP78 has been previously shown to provide cytoprotection to 
cells. 
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In this study MSA increased caspase-8 expression compared to baseline in THP-1 
cells but not PBMC (Figure 18). This Se-induced caspase-8 activation is in 
agreement with previous studies that have shown Se compounds induce apoptosis 
through caspase-8 mediation (Li et al. 2008). The fact that Se does not induce 
caspase-8 in PBMC may reflect that Se compounds preferentially induce 
apoptosis in malignant cells, not normal cells. This has been demonstrated in 
numerous studies, and has been detailed in section  1.9.3.  
3.5 Conclusions 
 
1. This in vitro model using PBMC from healthy blood donors and THP-1 
human leukaemia cells can successfully be used to evaluate the 
differential impact of MSA on these normal and malignant mononuclear 
white blood cells. 
2. While PBMC do not suffer reduced viability from short-term exposure to 
MSA, cisplatin, RT or their combination, MSA alone is cytotoxic to 
THP-1 cells and enhances the cytotoxic effects of cisplatin and RT 
against THP-1 cells. 
3. Total intracellular glutathione increases in PBMC in response to MSA 
whereas its levels fall in THP-1 cells, possibly mediating the differential 
effect of MSA on the cytotoxicity of cisplatin and RT in THP-1 cells. 
4. MSA, cisplatin and RT are each genotoxic to PBMC under the conditions 
used, especially RT, and cisplatin can reduce the formation of comets 
induced by other agents. 
5. MSA induces ER stress in both PBMC and THP-1 cells. While the 
response in PBMC is predominantly pro-survival, it is mixed in THP-1 
cells, which have elevated levels of UPR markers, though caspase 8 
expression is only induced from MSA in THP-1 cells. 
 
  
Chapter 4  
In vivo investigations 
4.1 Introduction 
This work towards an MSc was undertaken in conjunction with a clinical trial 
being conducted at the Regional Cancer Centre, Waikato Hospital. In this 
international, randomised, placebo-controlled, double-blind phase II trial patients 
with head and neck squamous cell carcinoma (HNSCC) were treated with a 7-
week radical course of concurrent cisplatin chemotherapy and RT (CRT) and were 
randomised to receive either SLM or matching placebo for 11 weeks, starting a 
week prior to CRT treatment.  
The primary objective of the trial was to assess whether SLM reduces the 
incidence of grade 3 or 4 mucositis in HNSCC patients treated with concurrent 
CRT over 7 weeks, with secondary endpoints including complete response rate, 
relapse-free survival, overall survival, quality of life, xerostomia, renal 
impairment, hearing loss, myelosuppression, chemoradiation dose delivery and 
safety.  
In patients recruited in Hamilton, additional endpoints included plasma free 
cisplatin and plasma selenium pharmacokinetics and pharmacodynamic markers 
of biological activity of Se, as detailed below. The pharmacokinetic analyses will 
be conducted by a different department at the University of Waikato, but the 
pharmacodynamic biomarker analysis constitutes the subject of this chapter. 
Unfortunately because the trial is not yet complete, the treatment allocation code 
has not yet been broken and analysis of the pharmacodynamic results according to 
treatment with SLM or placebo cannot be made at the time of writing this thesis. 
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4.1.1 Objectives 
The overall objective of this chapter was to evaluate to evaluate 
pharmacodynamic makers in HNSCC patients undergoing CRT. The specific 
objectives were: 
 
1. to evaluate the DNA damage of PBMC obtained from patients before and 
during treatment using the comet assay; 
2. to quantify VEGF-A and VEGF-R1 levels in plasma of patients before 
and during treatment; 
3. to quantify GPX3 levels in plasma of patients before and during 
treatment; and 
4. to evaluate changes in ER stress response markers to treatment. 
4.2 Methods 
4.2.1 Patient population  
Patients with HNSCC planned for definitive treatment with a 7-week radical 
course of CRT were recruited for this study, which was approved by the Northern 
Y Regional Ethics Committee and the Institutional Review Board at Roswell Park 
Cancer Institute, Buffalo, NY, USA (the study sponsor). The inclusion criteria 
included: patients over 18 years of age; adequate liver, renal and bone marrow 
function; PBMC count ≥ 2.0 x 109/L; ECOG performance status ≥3, and life 
expectancy > 3 months. Patients were excluded if they had been treated with 
cytotoxic chemotherapy, anticancer biological therapy, hormone therapy or 
radiotherapy within the last 4 weeks; unable to swallow or absorb study tablets; 
concurrent Se supplements; or medical conditions which would compromise 
patients or data integrity.  
4.2.2 Patient treatment 
After screening, patients gave written informed consent and were randomly 
allocated to receive SLM 3200 µg/m
2
 or matching placebo as capsules. In the first 
65 
 
week study capsules were taken twice daily to shorten the time to plasma steady 
state concentrations, then once daily for weeks 2–11. CRT started at the beginning 
of week 2. 
CRT consisted of seven weeks of external beam RT given in 2 Gy fractions five 
days a week for 7 weeks, to a total dose of 70 Gy. Cisplatin 100 mg/m
2
 was given 
intravenously on weeks 1, 4 and 7 with adequate hydration and anti-emetic 
measures. 
4.2.3 Collection of samples for pharmacodynamic biomarker 
analysis 
Blood for pharmacodynamic biomarker analysis was drawn from patients prior to 
starting study medication, at the end of week 1 (after SLM or placebo only), at the 
end of week 2 (after 1 week of CRT) and at the end of week 8 (after completion of 
CRT). 25 ml of whole blood was collected into EDTA tubes, 5 ml of which was 
analysed fresh in a comet assay and the other 20 ml was processed to extract 
PBMC for analysis of ER stress markers. 10 ml of blood was collected into a 
lithium heparin tube and plasma was separated in a refrigerated centrifuge. Five 
1ml aliquots of plasma were stored at -80 ºC until analyzed for VEGF-A, 
VEGFR-1 and glutathione peroxidase.  
4.2.4 Comet assay 
The alkaline comet assay developed by Singh et al (1988) was used to assess 
DNA damage in PBMC extracted from blood samples of HNSCC patients. The 
comet assay of PBMC extracted from buffy coats from healthy donors (see 
section  3.2.3) was used to confirm that conditions of the assay were working 
appropriately. The comet assay methodology is described in section  2.6. 
4.2.5 Plasma VEGF-A ELISA 
Plasma VEGF-A levels were measured with a human VEGF-A ELISA kit 
purchased from Abnova (catalogue number KA0166) and stored at 4 C until 
required. The assay was run according to the manufacturer’s directions. All 
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reagents were warmed to room temperature before use. Table 6 provides a list of 
the reagents provided and used in this assay. Standards were assayed in duplicate, 
and unknown samples were assayed in triplicate. 
The wash buffer was prepared by diluting the 20x stock solution to 1x with MQ 
water. Microwell strips were then washed twice by pipetting 400 µl of wash 
buffer with an 8-channel micropipette, with thorough aspiration inbetween 
washes. Following the last wash step, the microwell strips were tapped on an 
absorbent paper towel to remove excess wash buffer.  
Table 6.  Reagents used in the plasma VEGF-A assay 
 
100 µl of sample diluent was added to each of the standard wells, including the 
wells to be used as a blank. Wells which were going to contain the samples had 50 
µl of sample diluent aliquoted into them. 100 µl of VEGF-A standard (which was 
reconstituted at least 10 minutes earlier with sterile MQ water) was added to 
duplicate wells and mixed through repeated aspiration (final concentration of 
standard one = 1000 pg/ml). Using serial dilution, 100 µl of standard one was 
added into each of the following 2 wells, mixed thoroughly through aspiration, of 
which 100 µl was then aliquoted into the following 2 wells and so on. 100 µl from 
Component Amount 
Microwell plate coated with polyclonal antibody to human 
VEGF-A 
1 aluminium 
pouch 
Biotin-conjugate anti-human VEGF-A polyclonal antibody 120 µl 
Streptavidin-HRP 150 µl 
Human VEGF-A standard lyophilized, 2 ng/ml upon 
reconstitution 
2 vials 
Sample diluent 12 ml 
20x assay buffer (PBS with 1% Tween-20 and 10% BSA) 5 ml 
20x wash buffer (PBS with 1% Tween-20) 50 ml 
Substrate solution (tetramethyl-benzidine) 15 ml 
Stop solution (1N sulfuric acid) 15 ml 
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the last standard microwell was discarded so that all standards had 100 µl total 
volume. 50 µl of each plasma sample was then added in triplicate to sample wells. 
The microwell plate was then covered with an adhesive film and incubated at 
room temperature for two hours on a microplate shaker set at 100 rpm. 
During the incubation the 20x assay buffer was diluted to 1x with MQ water. 
Approximately 10 minutes before the incubation was completed the biotin 
conjugate was prepared by diluting the stock 1:100 with assay buffer. After the 
incubation was complete, wells were emptied and washed six times with wash 
buffer as before. 100 µl of biotin conjugate was then added to all wells, before the 
plate was once again covered with an adhesive film and incubated at room 
temperature for one hour on a microplate shaker set at 100 rpm. Streptavidin-HRP 
stock solution was diluted 1:100 with assay buffer approximately 10 minutes 
before the second incubation was completed. After the second incubation was 
complete, wells were emptied and washed six times as before. Following the 
washing steps, 100 µl of streptavidin-HRP was added into all the wells. The plate 
was once again covered with an adhesive film and incubated at room temperature 
for one hour on a microplate shaker set at 100 rpm. 
After the third incubation, the well were once again emptied and washed six times 
with wash buffer. 100 µl of TMB substrate solution was then added to all wells 
and incubated for an appropriate time in the dark. The colour development on the 
plate was monitored by using BMG Labtech FLUOstar OPTIMA plate reader set 
at 620 nm. The reaction was stopped when VEGF-A standard one (1000 pg/ml) 
reached an OD of 0.9, or as close to this value as possible, by adding 100 µl of 
stop solution (1N sulfuric acid) to all the wells. As with all additions of reagents 
in this assay, an 8-channel micropipette was used to uniformly distribute the stop 
solution to all microwells. Using the same plate reader, the absorbance of the 
wells was measured immediately using 450 nm as the primary wave length. A 
standard curve was constructed, which was used to determine the concentration of 
the samples. The concentrations of plasma samples were calculated by 
interpolation of the regression curve formula from the standard curve. 
68 
 
4.2.6 Plasma VEGFR-1 ELISA 
The human sVEGFR-1 ELISA kit (catalogue number ALX-850-264-KI01, 
manufactured by Bender MedSystems) was stored at 4  C until use. The sVEGFR-
1 assay is very similar to that of the VEGF-A assay in principle. A coloured 
product is formed in proportion to the amount of VEGFR-1 present in the wells 
and the OD450 is measured spectrophotometrically in order to quantify VEGFR-1. 
Standards and blanks were again measured in duplicate, samples in triplicate. 
Using an 8-channel micropipette, microwells were washed twice with 400 µl of 
1x wash buffer (20x diluted with MQ water) with thorough aspiration of 
microwell contents between washes. After the final wash, excess wash buffer was 
removed by tapping the plate on an absorbent paper towel. 100 µl of 1x assay 
buffer (20x diluted with MQ water) was added to all standard wells and 50 µl of 
1x assay buffer into sample wells. Reconstituted VEGFR-1 standard prepared at 
least 10 minutes earlier was added and diluted in the same fashion as the VEGF-A 
assay. This created two rows of human VEGFR-1 standard dilutions ranging from 
10 – 0.16 ng/ml.  
Table 7 illustrates the reagents provided with the assay kit. 
Table 7.  Reagents used in the plasma VEGFR-1 assay 
Component Amount 
Microwell plate coated with monoclonal antibody to human 
VEGFR-1 
1 aluminium 
pouch 
Biotin-conjugate anti-human VEGFR-1 polyclonal antibody 100 µl 
Streptavidin-HRP 150 µl 
Human VEGFR-1 standard lyophilized, 20 ng/ml upon 
reconstitution 
2 vials 
Conjugate diluent 20 ml 
20x assay buffer (PBS with 1% Tween-20 and 10% BSA) 5 ml 
20x wash buffer (PBS with 1% Tween-20) 50 ml 
Substrate solution (tetramethyl-benzidine) 15 ml 
Stop solution (1M phosphoric acid) 15 ml 
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50 µl of plasma samples were then added in triplicate to sample wells. 50 µl of a 
1:100 dilution of the stock biotin conjugate (diluted with conjugate diluent) was 
prepared and added to all wells. Following the addition of the biotin conjugate, 
the microplate was covered with an adhesive film and incubated at room 
temperature for two hours, shaking on a microplate shaker at 100 rpm. 10 minutes 
before the end of this incubation, the streptavidin-HRP solution was diluted 1:200 
with the conjugate diluent. After the plate had been incubating for two hours, the 
wells were emptied and washed four times with wash buffer, with thorough 
aspiration inbetween washes. Excess wash buffer was tapped out on an absorbent 
paper towel. 100 µl of the diluted streptavidin-HRP solution was then added to all 
the wells. The plate was once again covered with an adhesive film, and incubated 
at room temperature for one hour on a microplate shaker at 100 rpm. 
Finally, after incubating the wells with the streptavidin-HRP solution, wells were 
emptied and washed four times according to the previous wash step. 100 µl of 
TMB substrate solution was then added to all the wells, and colour development 
monitored at 620 nm using BMG Labtech FLUOstar OPTIMA plate reader. Stop 
solution was added when standard one (10 ng/ml) reached an OD of 
approximately 0.9. Once the reaction was stopped, the OD450 was measured 
immediately. A standard curve was constructed and used to determine the 
concentration of unknown plasma samples. The concentrations of plasma samples 
were calculated by interpolation of the regression curve formula from the standard 
curve. 
4.2.7 Plasma glutathione peroxidase-3 ELISA 
ELISA was used for the quantitative determination of glutathione peroxidase-3 
(GPX3) in human plasma. The GPX3 (human) ELISA Kit (catalogue number AG-
45A-0020EK-KI01) was purchased from AdipoGen 
TM
 and stored at 4 C until 
use. All samples and kit components were equilibrated to room temperature 
before being used. Table 8 lists the components used in this assay. 5x wash and 
diluent concentrates were diluted to 1x with MQ water. The 100x detector was 
diluted to 1x with 1x diluent just prior to use. 1ml of MQ water was added to the 
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GPX3 standard to make a stock concentration of 64 ng/ml. Standards and samples 
were assayed in duplicate. 
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Table 8.  Reagents used in the plasma glutathione peroxidase-3 assay 
 
Using an 8-channel micropipette, 100 µl of 1x detector was pipetted into each 
standard well including the blanks. Using a micropipette 100 µl of the stock 
standard was pipetted in to the top two wells for a final concentration of 32 ng/ml 
(denoted standard one). Standard one was thoroughly mixed through repeated 
aspiration. Serial dilution was then used to prepare the rest of the standards by 
pipetting 100 µl of standard one into the below well and so on, until a total of 
seven standards were prepared in duplicate (32 ng/ml – 0.5 ng/ml). Plasma 
samples were diluted 200x by mixing 5 µl of sample with 995 µl of 1x diluent. 
100 µl of each diluted sample were pipetted into wells. The plate was then 
covered with an adhesive film and incubated at 37  C for one hour. Following this 
incubation the adhesive film was removed and the wells emptied. Using an 8-
channel micropipette, all wells were washed 3 times with 300 µl of 1x wash 
solution, with aspiration of wash solution from wells between washes. After the 
final wash step, the wells were emptied, and the plate tapped on a dry absorbent 
paper towel to remove excess wash solution.  100 µl of secondary antibody was 
then added to each well and the plate was incubated at 37  C for another hour. 
Component Amount 
Microwell plate coated with biotinylated polyclonal 
antibody to human GPX3 
1 aluminium 
pouch 
5x wash concentrate 100 ml 
5x diluent 50 ml 
Secondary antibody 12 ml 
100x detector 150 µl 
GPX3 standard 1 vial 
Substrate I 6 ml 
Substrate II 6 ml 
Stop solution  12 ml 
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After this incubation the wells were emptied, and washed three times as 
mentioned previously. 
Substrate solution was prepared by adding one part substrate I with one part 
substrate II. 100 µl of substrate solution was added into all wells and incubated in 
the dark at room temperature. After 20 minutes, 100 µl of stop solution was added 
into all wells using an 8-channel micropipette. The OD450 was measured using 
BMG Labtech FLUOstar OPTIMA plate reader, and the standards used to prepare 
a standard curve. The concentrations of plasma samples were calculated by 
interpolation of the regression curve formula from the standard curve. 
4.2.8 ER stress response markers in PBMC 
The methodology for analysis of the ER stress response proteins GRP78, 
phosphorylated elF2α, CHOP, spliced XBP1, and caspase-8 is detailed in section 
 2.7. Additional details are described below. 
4.2.8.1 Protein isolation from patient PBMC 
PBMC were isolated as described in section  2.1. However after the final wash step 
the PBMC pellet was resuspended in 500 µl of sterile PBS pH 7.4. This cell 
suspension was transferred to a 1.7 ml tube where an equal volume of 2 x 
Laemmli buffer (0.25 M Tris pH 6.8, 5% SDS, 20% glycerol, 1% 2-
mercaptoethanol (v/v), 0.02% bromophenol blue (w/v)) was added.  The Laemmli 
protein suspension was vortexed thoroughly for 10 seconds before being 
incubated at 95  C for 10 minutes. Following incubation the protein lysate was 
vortexed for another 10 seconds before being stored at -80 C. 
4.2.8.2 Protein quantification from Laemmli buffer 
Laemmli buffer contains a number of substances that interfere with various 
protein quantification methods. Therefore, a number of methods were trialled in 
order to obtain accurate quantification of protein: protein was precipitated with 
50% trichloroacetic acid or acetone, and quantified by measuring the 280nm 
absorbance; using the Bradford assay; or using the BCA assay previously 
described in Chapter 2. Both the 280nm and Bradford methods failed to accurately 
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quantify protein concentration (data not shown), however, the BCA method 
proved to be reliable and will be described below.    
4.2.8.2.1 BCA method 
Protein lysates in Laemmli buffer stored at -80 C where incubated for 10 minutes 
at 95 C. Tubes were vortexed for 10 seconds then placed on ice. 6.25 µl of the 
protein lysate was aliquoted to a new 0.6 ml tube. 43.75 µl of RIPA buffer was 
added and mixed thoroughly by repeated aspiration with a micropipette before 
200 µl of -20 C acetone was added. At the same time, 25 µl of BCA standards 
were pipetted into 0.6 ml tubes and 200 µl of -20 C acetone was added. 
Unknown sample tube(s) and BCA standards were then incubated at -20 C for 30 
minutes before pelleting precipitated protein by centrifugation at 13,200 rpm for 
10 minutes at 4 C. The supernatant was subsequently removed with a 
micropipette and tubes were allowed to stand for 20 minutes in order to evaporate 
residual acetone. 25 µl of RIPA buffer was added into each tube which was then 
vortexed thoroughly. It should be noted that the pellet was unable to be 
resuspended. 200 µl of BCA (50:1) reagent was then added (the pellet became 
soluble at this point) and tubes were incubated at 37 C for 30 minutes. Following 
the incubation, tubes were immediately placed on ice and the OD562 was measured 
by aliquoting 2 µl of standard, or sample, onto the pedestal of a NanoDrop ND-
1000 Spectrophotometer. Standards were measured first in triplicate to prepare a 
standard curve. Sample values were then measured in triplicate, and protein 
concentrations calculated using the prepared standard curve. 
4.3 Results 
Recruitment into the clinical trial started later than anticipated and thus only eight 
patients were accrued over the period that this laboratory study was conducted, 
rather than the 16 anticipated. For various reasons not all patients had the full set 
of blood tests planned in the protocol, and one patient withdrew from the trial 
within 2 weeks of starting and only had a set of samples taken at baseline. The 
time points at which each patient had samples taken that could be analysed for 
each assay is shown in Table 9. 
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Table 9.  Details of samples from each patient available for 
pharmacodynamic assays  
 
Patient Baseline Week 1 Week 2 Week 8 
A • • • • 
B • • • • 
C • • • • 
D • 
 
• • 
E 
 
• • 
 F • • • 
 G • •     
H • 
   
 
     
4.3.1 Comet assay 
 
The comet assay used in this study was unable to detect any DNA damage in 
PBMC from patients with HNSCC (all scores = 0). Figure 19 illustrates a patient 
comet as well as a positive control. These pictures are representative of all comet 
assays carried out on patient samples.  
Figure 19. Comet assay examples: A: THP-1 positive control; B: PBMC from 
patient in the HNSCC trial. 
A B 
• denotes obtained samples 
 
A B 
75 
 
4.3.2 Plasma VEGF-A 
Plasma VEGF-A concentration-time profiles in Patients A – F are shown in 
Figure 20 (results of Patients G and H can be found in the Appendix B).  
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Figure 20.  Plasma VEGF-A concentration-time profiles (* p < 0.05, ** p < 
0.005, *** p < 0.0001). 
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4.3.3 Plasma VEGFR-1 
Plasma VEGFR-1 concentration-time profiles in Patients A – F are shown in 
Figure 21 (results of Patients G and H can be found in the Appendix B). 
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Figure 21.  Plasma VEGFR-1 concentration-time profiles (* p < 0.05, ** p < 
0.005, *** p < 0.0001). 
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4.3.4 Plasma GPX3 
Plasma VEGFR-1 concentration-time profiles in Patients A – F are shown in 
Figure 22 (results of Patients G and H can be found in the Appendix B). 
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Figure 22.  Plasma GPX3 concentration-time profiles (* p < 0.05, ** p < 
0.005, *** p < 0.0001). 
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4.3.5 ER stress response 
Unfortunately full data sets were unable to be obtained but available results of 
pro-survival and apoptotic ER stress proteins measured in trial patients are 
presented in Figure 23. 
Figure 23: ER stress markers in HNSCC patients 
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4.4 Discussion 
4.4.1 Comet assay 
The comet assay has been used successfully in assessing endogenous or induced 
DNA damage of PBMC from human samples in numerous studies (Blasiak, 
Kowalik, Malecka-Panas, Drzewoski, & Wojewodzka, 2000; A. Collins, et al., 
1997; Dusinska & Collins, 2008; Erkekoglu, et al., 2010; Kopjar, Garaj-Vrhovac, 
& Milas, 2002; Kotsopoulos, et al., 2010; Laffon, Valdiglesias, Pasaro, & 
Mendez, 2010; Santos, et al., 2009). In this study we assessed endogenous DNA 
damage of PBMC from HNSCC patients undergoing cisplatin and radiation 
treatment. The conditions of this assay were unable to detect any DNA damage, 
and conditions were shown to be working with other cells. However, this is not 
necessarily due to there being no damage present in cells from patients. RT is a 
potent inducer of DNA breaks, as shown in PBMC in the in vitro investigations 
detailed in section  3.3.3. Cisplatin is known to induce DNA inter- and intra-strand 
cross-links and previous work has demonstrated that cisplatin reduces the 
formation of comets in vitro (Merk & Speit, 1999; Pfuhler & Wolf, 1996). These 
authors concluded that the comet assay is a very sensitive tool for detecting the 
presence of cross-links through the reduction of comets. Therefore it would 
appear that the treatment of patients in this study with cisplatin has prevented the 
RT-induced DNA breaks in these patients’ PBMC from resulting in DNA 
fragmentation that can be detected by the comet assay. 
Since the aim of this investigation was to assess total DNA damage present in 
PBMC from patients being treated with both cisplatin and RT, and any effects of 
SLM on this, it would appear that the comet assay is not suitable at all for this 
purpose. If patients were undergoing RT treatment alone the comet assay may be 
more useful to detect total DNA damage in PBMC and an effect of SLM or other 
Se compounds could be investigated. 
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4.4.2 Markers of angiogenesis  
4.4.2.1 VEGF-A 
In this study, patients with HNSCC were randomized to either 3200 µg/m
2
 SLM 
or placebo. While no indication of what study treatment patients received has been 
revealed at this point, there are intriguing results when examining individual 
patient responses during treatment.  
In this study cohort inconsistent changes in plasma VEGF-A levels during therapy 
were seen. Two patients who continued with the trial until completion showed a 
significant increase in VEGF-A levels compared to baseline after eight weeks (B, 
D). Two other patients who participated in the trial for the full duration showed a 
significant decrease in VEGF-A from baseline at 8 weeks (A), and no change (C).  
The significance of these changes is uncertain as longitudinal studies of changes 
in VEGF-A in patients during a course of treatment have not been described. 
However these changes might carry prognostic significance for the outcome of 
treatment given the importance of VEGF-A to tumour progression and metastasis. 
It is a well accepted that angiogenesis is essential for the growth and metastasis of 
solid tumours and there has been considerable research evaluating the association 
of angiogenic markers and the prognosis of various malignancies. Through 
examining the relationships between VEGF-A, microvessel density, epidermal 
growth factor, human papilloma virus, response to radiotherapy and clinical 
outcome in 85 tonsillar squamous cell carcinoma patients, Fie et al. (2009) 
showed that VEGF-A levels correlated with microvessel density and was 
associated with a poor prognosis. Similarly, Sullu and colleagues (2010) showed 
that VEGF-A expression may be important in the outcome of squamous cell 
carcinoma of the larynx. The authors found that the tumour grade was 
significantly associated with VEGF-A expression, and microvessel density was 
significantly higher in high-grade tumours. Furthermore, VEGF-A levels were 
correlated with the size of the tumour and lymph node metastasis. Another study 
involving 54 specimens of oral squamous cell carcinomas showed that tumour 
specimens, when compared to pre-neoplastic and normal tissues, had significantly 
elevated levels of VEGF-A (Margaritescu, et al., 2010). The poor prognosis 
associated with high VEGF-A expression and tumour metastasis has also been 
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confirmed in a number of other studies (Joo, Jung, Kim, & Sun, 2009; Onesto, et 
al., 2006; Tse, et al., 2007). 
Given the poor prognosis associated with elevated levels of VEGF-A, as well as 
the reliance on VEGF-A expression for tumour progression, a number of studies 
have been carried out evaluating the effect of combining angiogenesis inhibitors 
with anticancer treatments. Examining the effects of bevacizumab, a monoclonal 
antibody that inhibits VEGF-A, Fujita et al. (2007) showed a dramatic inhibition 
of HNSCC xenografts in mice. When bevacizumab was combined with paclitaxel, 
another cytotoxic agent, there was a synergistic inhibition of tumour growth 
compared to using either agent separately. Furthermore, the authors showed that 
the microvessel density in tumours was reduced. Kruser et al. (2010) showed 
using a human HNSCC xenograft model that targeting the mediators of VEGF-
A’s action with motesanib, a potent inhibitor of VEGF receptors (including 
VEGF-R2), increased radiation sensitivity. These in vitro and in vivo data provide 
compelling evidence that VEGF-A, and the receptors which mediate the 
biological effects of VEGF-A, play an important role in the long-term response of 
HNSCC to treatment. The importance of these elevated levels of VEGF-A may be 
of clinical significance in later follow ups. 
4.4.2.2 VEGFR-1 
In this study VEGFR-1 levels changed inconsistently over the course of CT and 
RT. Only patient D had a significant increase in VEGFR-1 levels at eight weeks 
compared to baseline with other patients having very variable response during the 
treatment course. Patient C had a significantly reduced level of VEGFR-1 
compared to baseline at eight weeks. These data indicate that angiogenesis 
mediators do indeed change during CT and RT in patients with HNSCC and that 
this response differs from patient to patient. 
VEGFR-1 expression in tumours has been associated with poor survival in 
various cancers (Hirashima, et al., 2009; Okita, et al., 2009). Although the role of 
VEGFR-1 is not fully understood, it has been shown to be specifically involved in 
neoangiogenesis in vivo (Huusko, et al., 2010), in vascular branching (Kearney, et 
al., 2004) and activation of macrophage-lineage cell migration into tumour tissue 
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(Barleon, et al., 1996; Kerber, et al., 2008; Krysiak, et al., 2005; Muramatsu, 
Yamamoto, Osawa, & Shibuya).  
As mentioned earlier, the same patient (D) shows a concurrent increase in VEGF-
A and VEGFR-1 levels. This is interesting as increased levels of both VEGF-A 
and VEGFR-1 may reflect a poor survival outcome, which is consistent with 
previous studies (Fei, et al., 2009; Hirashima, et al., 2009; Joo, et al., 2009; Okita, 
et al., 2009; Onesto, et al., 2006; Sullu, et al., 2010).  
4.4.3 Antioxidant capacity 
This study investigated the levels of GPX3 in plasma of patients with HNSCC 
undergoing CT and RT.  Plasma levels of GPX3 were shown to significantly 
change in relation to baseline in five of six patients examined, though 
inconsistently. Patient A showed no significant change in GPX3 levels during 
treatment, but at eight weeks GPX3 levels were significantly elevated. Patient C 
showed significantly elevated levels of GPX3 levels during treatment, but at eight 
weeks GPX3 had decreased to a level close to baseline. Patients B and D both 
showed decreased antioxidant capacity during treatment, which was maintained 
up to eight weeks.  
It is difficult to interpret this study data without knowing whether each patient 
received SLM or not, but the results in the last two patients are consistent with 
previous studies that have demonstrated that cisplatin reduces antioxidant 
capacities of patients (Gupta, et al., 2010). Moreover, patients undergoing RT 
have been shown to have significantly reduced plasma Se levels after treatment 
compared to pretreatment levels (Franca, et al., 2010). There is little information 
regarding the expression of GPX3 during and after CT and RT.  
Given that selenoprotein expression and activity is dependent on Se status, it is 
likely that the antioxidant capacity of patients would be reduced concurrently with 
lower plasma Se levels. Conversely, Se supplementation at high doses should 
increase GPX3 levels, unless patients had high baseline plasma Se that had 
already saturated GPX activity; indeed supplementation with as little as 200 µg of 
Se a day can saturate plasma GPX activity (Thomson, Robinson, Butler, & 
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Whanger, 1993). Thus the changes seen with several thousand micrograms of 
SLM are likely to be a lot less than might be expected. 
Before treatment, cancer patients present with low-antioxidant levels and cancer 
therapies typically reduce the antioxidant capacity of the patient (Ladas, et al., 
2004). Radiation damages cells directly by producing ROS which cause double-
stranded DNA breaks, and altering other molecules in the cell. ROS formation is 
also one of the main mechanisms of many CT drugs, including cisplatin (Block, et 
al., 2007), and these ROS can often be the source of unwanted side-effects.  
This raises an interesting debate as to the usefulness of antioxidant 
supplementation during anticancer therapies. Block et al. (2007) systematically 
reviewed the literature of antioxidant supplementation in combination with 
chemotherapy and found that antioxidant supplementation during chemotherapy 
resulted in fewer toxicities, allowing uninterrupted dosing. Reducing unwanted 
side-effects could lead to increasing continuation of treatment, as opposed to 
patients terminating treatment early due to unwanted toxicities. While none of the 
studies showed poorer outcomes in terms of survival, they were generally 
underpowered and poorly-designed to answer this question. Whether the activity 
of ROS can be safely blocked with antioxidants without compromising the 
anticancer efficacy of CT and RT remains to be determined. 
It is questionable whether any improvement in antioxidant activity induced by Se 
supplementation significantly contributes to its modulation of the efficacy and 
toxicity of CT and RT, as the relative increase in antioxidant activity is likely to 
be modest, as discussed above, and there are several other mechanisms through 
which Se appears to mediate these modulatory effects. Nevertheless, the overall 
impact of Se in cancer trials appears to be beneficial. Most recently a phase III 
multicenter trial of RT + CT for cervical and uterine cancer reported that Se 
supplementation reduced the proportion of patients experiencing severe diarrhoea 
from 46% to 21% (Muecke, et al., 2010).  
4.4.3.1 Antioxidant capacity and angiogenesis 
Interesting observations can be made when GPX3 levels are compared to VEGF-
A levels. Both patients B and D, who had significantly reduced GPX3 levels at 
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eight weeks also had significantly elevated levels of VEGF-A. Conversely, 
elevated levels of GPX3 in patient A were accompanied by significantly reduced 
levels of VEGF-A.  
This is consistent with previous observations that have shown that ROS play a 
critical role in not only normal, but also tumour angiogenesis (Maulik, 2002). 
Hydrogen peroxide treatment causes significant induction of VEGF expression 
which is blocked by antioxidants (Brauchle, Funk, Kind, & Werner, 1996). It has 
been shown that enhanced levels of hydrogen peroxide promote angiogenesis 
through the inhibition of PHD proteins leading to the accumulation of HIF 
(Komatsu, Kato, Nakayama, Miyagawa, & Kamata, 2008). As VEGF induction is 
dependent on HIF (Giaccia, et al., 2003), HIF accumulation leads to increased 
levels of VEGF-A. ROS are also involved in angiogenesis as down-stream 
signalling intermediates of VEGF-A (Colavitti, et al., 2002; Parenti, et al., 1998) 
Various antioxidants have been shown to reduce angiogenesis. Antioxidants 
derived from Ginkgo biloba leaves were demonstrated to inhibit lymphocyte-
induced angiogenesis (Monte, Davel, & de Lustig, 1994) and various other free 
radical scavengers, including thiol compounds, have been shown to inhibit the 
induction of macrophage-mediated angiogenesis (Fidelus, 1988; Koch, Cho, 
Burrows, Leibovich, & Polverini, 1988). T cell-induced angiogenesis is reliant on 
ROS (Fidelus, 1988) with hydrogen peroxide directly being involved in the 
angiogenic response (Monte, Davel, & Sacerdote de Lustig, 1997).  
This inverse relationship between antioxidant activity and angiogenesis is 
consistent with data presented in this study, although admittedly the numbers of 
patients examined is too small to draw any conclusions in this regard. Similarly it 
is tempting to speculate that, given the decrease in antioxidant capacity of patients 
undergoing CT or RT from previous studies, patient A and C may well have 
received the SLM instead of placebo, as GPX3 levels at week eight were 
increased or maintained respectively. Conversely, patient B and D may have 
received placebo as both patients at week eight had significantly lower GPX3 
levels and corresponding increase in angiogenic markers. 
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4.4.4 ER stress response 
This study attempted to assess ER stress markers in HNSCC patients undergoing 
CRT. ER stress is an important mechanism in cancer therapeutics as demonstrated 
by the proteosome inhibitor bortezomib, which induces ER stress, and thus 
apoptosis, through increasing aberrantly-folded proteins (Szegezdi, et al., 2006). 
Se supplementation has been shown to act through targeting mediators of the ER 
stress signal (Wu, et al., 2005), resulting in an increase in apoptosis.  
Additionally, Se appears to selectively sensitize tumour cells to a number of 
therapeutic drugs while at the same time increasing the resistance towards these 
drugs in normal cells (Cao, et al., 2004). This differential effect of Se 
administration on ER stress could, in part, account for the enhanced therapeutic 
efficacy of Se supplementation.  
Unfortunately, full data sets of ER stress markers in patients were unable to be 
generated at this time. However, what is clear, in the three patients analysed, is 
that caspase-8 expression is modulated during CRT. What is interesting is that 
caspase-8 expression seems to be opposite that of pro-survival ER markers in 
PBMC, as expected. In patient A there were elevated levels of phospho-eIF2α at 
baseline. Expression of phospho-eIF2α decreased in week one and two compared 
to baseline, which coincided with increased levels of caspase-8 (Figure 23). At 
week 8, phospho-eIF2α levels were restored and caspase-8 levels were reduced. In 
patient B, spliced XBP1 was present at very high levels at week one. This also 
coincided with a slight decrease in caspase-8. When spliced XBP1 levels were 
reduced at weeks two and eight, caspase-8 levels were present at a higher 
abundance. A more complete data set would help to build a fuller picture, 
especially in the context of whether each patient had supplemental SLM or not. 
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4.5 Conclusions  
1. The comet assay as used in this investigation is not a useful tool to use 
in assessing DNA damage in patients undergoing CRT, most likely due 
to DNA-cross-linking effects of cisplatin. 
2. VEGF-A and VEGF-R1 levels are modulated in response to CRT but 
the absence of information on study treatment assignment means further 
interpretation is not feasible. 
3. GPX3 levels are modulated in response to CRT and appear to be 
increased or maintained in patients that present more favourable levels 
of mediators of angiogenesis . 
4. Insufficient data is available to adequately evaluate ER stress responses 
in PBMC from patients, though in general caspase-8 expression 
increases over time, as might be expected in cells exposed to CRT. 
 
  
Chapter 5  
General discussion 
The overall goal of this work was to assess the biological effects of Se, cisplatin, 
RT and their combination on malignant and non-malignant cells, to provide 
insights into the biological markers which may be informative in clinical trials 
using Se compounds to modulate the efficacy and toxicity of CT and/or RT. Se 
compounds have been previously been shown to inhibit cell growth and inhibit 
apoptosis in a variety of tumour cell lines in vitro (Cho, Jung, & Chung, 1999; 
Jung, Zheng, Yoon, & Chung, 2001; Zeng, 2002). Furthermore, the effects of Se-
induced apoptosis seem to be preferentially induced in malignant cells, not normal 
cells.  
This study investigated the impact on cell viability of MSA, which provides a 
steady stream of methylselenol, the Se metabolite thought to mediate the 
therapeutic properties of Se. MSA was shown to inhibit THP-1 leukaemia cell 
growth and sensitize these cells to cisplatin and RT. Given these data, total GSH 
levels and various proteins known to be involved in ER stress and apoptosis were 
evaluated in both PBMC (from healthy donors) and THP-1 cells.  GSH levels 
were shown to be dramatically reduced in response to MSA in THP-1 cells, while 
PBMC GSH levels increased under the same conditions. This is significant as 
GSH plays a pivotal role in a cell’s ability to reduce toxic stress. These 
observations are consistent with previous studies that have shown that Se 
treatment modulates the sensitivity of tumours by reducing levels of total 
intracellular GSH.  
ER stress markers were assessed and shown to be modulated in response to MSA. 
Pro-survival UPR proteins were upregulated in PBMC treated with MSA while no 
induction of the pro-apoptotic proteins CHOP or caspase-8 was observed. 
Conversely, caspase-8 in THP-1 cells was upregulated in response to MSA. The 
clinical trial also planned to evaluate the response to SLM of ER stress markers in 
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PBMC from HNSCC patients undergoing CRT. The exact pattern of ER stress in 
these clinical samples is still not clear, though the limited data available suggests 
that caspase-8 is increased in response to patient treatment and this modulation 
seems to be opposite to pro-survival UPR markers. This is consistent with the 
expected inhibition of protein translation due to phosphorylation of eIF2α, which 
would result in lower levels of pro-apoptotic protein translation, including 
caspase-8, and an increase in pro-survival proteins including spliced XBP1. 
The importance of angiogenesis in tumour survival has been extensively 
documented (Fei, et al., 2009; Hirashima, et al., 2009; Joo, et al., 2009; Okita, et 
al., 2009; Onesto, et al., 2006; Sullu, et al., 2010). Patients that present with high 
levels of VEGF-A or VEGF-R1 typically have a poor prognosis. In this study the 
levels of both VEGF-A and VEGF-R1 were monitored in patients before and 
during treatment. Interestingly angiogenesis markers appeared to be upregulated 
at week 8 in patients that had significantly reduced GPX3 levels compared to 
baseline. Section  4.4.3.1 discussed the importance of antioxidant regulation in 
relation to angiogenesis. What may be occurring here is that high doses of Se 
modify tumour angiogenesis via an antioxidant mechanism, though this possibility 
has to be further evaluated. 
Future clinical studies could usefully evaluate the effects of Se treatment on 
intracellular GSH in PBMC, as this appears to be a sensitive marker of Se effects, 
and determine the dose-response relationship for this effect. An increase in 
intracellular GSH in PBMC may parallel an increase in other normal tissues in 
response to Se supplementation that may, in part, mediate the observed benefits of 
Se in reducing toxicity of both CT and RT without compromising treatment 
efficacy.  
 
There is insufficient data from this study to evaluate whether markers or 
angiogenesis or ER stress response may be useful indicators of Se effects in 
PBMC, and further evaluation of this in patients is warranted before any 
recommendation can be made. Similarly plasma GPX3 responses to Se cannot be 
adequately characterised from this study.  
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Overall this study has achieved part of its objectives, in defining the biological 
characteristics of the differential impact of Se on malignant and non-malignant 
cells in humans, with and without CT and RT. The results merit further 
investigation to better characterise the cellular responses and their potential 
clinical significance. 
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